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INTRODUCTION     
Alcoholic Liver Disease1  
                                     Chronic and excessive alcohol ingestion is one of the major cause 
of liver disease the pathology of alcoholic liver injury. Comprises of three major lesions, 
rarely existing in a pureform 1. Fatty liver 2. Alcoholic hepatitis and 3. Cirrhosis. 
Prevalence2    
                   Alcoholic liver disease is foremost health risk in developing countries, and it 
ranks third in developed countries,  Daily ethanol consuption exceeding 40-80g% day for 
males, and  20-40g% day for females for 10-12yrs will almost certainly lead to alcoholic 
liver diaease.  alcoholism is not only a major health problem, but also social problem in 
low economic status in india.                                 
                    Epidimiological study in 2000 reported that 3% of all deaths one due to 
alcoholic  Liver disease, in which 17% are men, 7% are women.3  In 2005 an assessment 
by WHO 3.2% of  all deaths, and 4% of the impact of the diaease, were  due to alcohol.4  
                    The prevalence of alcoholism in higer in young men, adults, unmarried, and 
unemployed5.  Amoung the alcoholic people the rate of mortality, is highest for alcoholic 
hepatitis is  about 50% .In long term of alcoholism, 20%  of alcoholics develop fatty liver, 
and 10-15% of people develop Cirrhosis6. 
As per siddha text the kalleeral noi is caused by increased level of pitha kutram7. 
Pavattaiver  kudineer chooranam( pavetta indica.L) is herbal drug mentioned in 
gunapadam Mooligai vaguppu 1 part.8 Pavattaiver  kudineer chooranam has not been 
evaluated for hepatoprotective  activity so for.  
based on the literature evidence hence the researcher has selected the drug   for 
Hepatoprotective  activity and therapeutic efficacy for kalleeral noi.     
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AIM: 
 To evaluate the safety and efficacy of Pavattaiver kudineer chooranam, for 
Hepataprotective activity on Kalleeral noi. (Alcoholic Liver Disease) 
OBJECTIVE: 
Primary objective: 
To evaluate the Hepatoprotective activity of Pavattaiver Kudineer  Chooranam.  
Secondary objective: 
 To evaluate the efficacy of Pavattaiver Kudineer  Chooranam,  in the management 
of Kalleeral noi (Alcoholic Liver Diseases). 
 1. Collection of evidences in siddha literature  
 2. Collection of evidences in botanical aspects. 
 3 . Standard operative procedure  
 4. Biochemical analysis  
 5. High performance thin layer chromatography 
 6. Physical properties    
  7. Pharmacological study   
 8. Clinical study: A pilot study on trail medicine 
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PVATTAIVER KUDINEER CHOORANAM 
MATERIALS AND METHODS 
STANDARD OPERATIVE PROCEDURE 
Collection of the raw drug: 
  The raw drug was collected from  Ramasamy chetty shop paris Chennai, 
and. authenticated by competent in department of gunapadam.  
Purification process: 
Purification of Pavattai Root (Pavetta indica) Linn  
  Pavattai Root was washed in water 9 
Preparation of the test drug: 
  The purified root was dried in the shadow. The dried root was pulverised 
by an Electric grinder in to coarse powder. The powder was stored in a clean, dry air tight 
container. 
LABELLING:  
Name of the preparation    : Pavattaiver kudineer Chooranam. 
Taste                  : Kaippu (bitter) 
Colour                : Mild brown colour 
Dose                   : 50gm b.d.(50ml) 
Duration                : 30 days  
Indication                 : Kalleeral noi 
Date of manufacture         : The drug was prepared in three batches. 10.3.12, 15.4.12  
           20.6.12 
Expiry                    : 3 months from the date of manufacture. 
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Pavetta indica(Lin) 
 
 
 
Root of  Pavetta indica( Lin) 
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Pavattaiver kudineer chooranam 
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REVIEW OF THE LITERATURE 
GUNAPADAM ASPECT 
ght£il  Pavattai8 
Pavetta  indica.Linn 
ntW bga® :- g‰gz« 
Tel- Paputta – Vargras   Nooni - Papoota  
Sans- Pappana 
Mal- Malliamothu 
 Hind- Kankra  
 Kan. Pavate 
ïJ v§F« »il¡F«, F¤J¢ brotF¥ig nr®ªjJ. 
 g.c : ïiy, fhŒ, nt®. 
 Rit : if¥ò, fh®¥ò, j‹ik... bt¥g«, ãÇî - fh®¥ò 
brŒif  
 kyÄs¡»  kyfhÇ  Laxative 
 cukh¡»  gyfhÇ    Tonic 
ïiy Fz« :  ïjdhš, tË, Ia¡T£lhš ãwªj nehŒfŸ,  jhfRu«, K¥ãÂ 
ïit Ú§F«. gá c©lhF«.    
   Ójth j§fsWª Ôgdnkh c©lhF«.  
   thj§ fgbkhÊí« th®FHny - nghjnt 
  Mt£il¤ jhfRu« m‰WÉLª njhl«ngh« 
  ght£il¥ g¤âÇ¡F¥ gh®.  (m.F.) 
fhŒ: ïjdhš, tË Ru«, mUá, Ój¡fL¥ò, Ia¡F‰w«, fÊ¢rš ïit Ú§F«.  
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thj Ru«jÂí« thaUá v»ÉLŠ 
Ój¡fL¥gfYª njbkhÊna! - thJòÇ 
ã¤jtâ rhubkhL nguh¡ fgKkW« 
c‰wgh t£l§fhŒ¡F«. 
 ïiyia¡ FoÚÇ£L¡ bfhL¡f, nk‰T¿a nehŒfŸ nghF«. ïiyia 
tj¡» it¤J¡ f£l, ÑœthÆY©lhF« vÇ¢rš jÂí«. 
ntiu FoÚÇ£L 40-80 Ä.È. âdÄU ntis bfhL¡f, <uš nehŒfŸ, 
thjRu«, Rit m¿ahik ngh«. ï¤Jl‹ á¿J R¡F¢ nr®¤J¢ nrhif nehŒ¡F¡ 
bfhL¡f, Úiu ïw¡F«. 
ght£il nt®¡ FoÚ®: 
TW»‹w ght£lil bfh©lnj u©lKl‹ 
åWl‹nt È¥gU¤â ntÇití§ - fhW»‹w 
e‹ÄsF§ T£o eakh¡ »ahHÄ£L© 
br‹kÆiy ahkRuŠ br¥ò: 
  ght£il nt®, á‰whkz¡Fnt®, c¤jhkÂnt®, ÄsF KjÈat‰iw 
Xbuilahf¡ T£o, ïo¤J¡ FoÚ® brŒJ Fo¤Jtu, brÇah Ru« v‹W« 
thuhbjhÊí«. (nj. FoÚ® 100) 
nt®¥ bghoia xU 4 »uh« vL¤J, á¿J R¡F¢ nr®¤J¢ r®¡fiu fyªJ 
áW FHªijfS¡F¥ òf£l, ty¥gh£Ouš, ïl¥gh£Ouš, å¡f« Ú§F«. 
nt®¥bgho, R¡F¤öŸ ï›Éu©ilí« Xbuil nr®¤J, fGÚÇš fy¡»¥ 
bgUtÆ‰W¡F¡ bfhL¡f, Úiu t‰w¢ brŒí«. 
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  À¡Åð¨¼ §ºÕõ À¢È ÁÕóÐ¸û:   
· Å¡¾ÍÃ ¸¢Â¡Æõ:10  
    «Ç×; 1«×ýî Å£¾õ, ¾¢Éõ 3§Å¨Ç 
    ¾£Õõ §¿¡ö¸û; Å¡¾ÍÃõ 
 
· À¡Åð¨¼Â¡¾¢ ¸‡¡Âõ:11  
    «Ç×; 8 ø ´Õ ÀíÌ ÅÊ¸ðÊ ¯ð¦¸¡ûÇ×õ 
     ¾£Õõ §¿¡ö¸û; ƒ£Ãõ 
 
· À¡Åð¨¼ì ÌÊ¿£÷:12 
     «Ç×: Å¢¾¢ÀÊÌÊ¿£÷ ¦ºöÐ ÌÎòÐ ÅÃ  
     ¾£Õõ §¿¡ö¸û; ¬ÁÍÃõ ¾£Õõ 
· ÀÅð¨¼ «¨ÃôÒ:12 
     «Ç×:  ¦¸¡ð¨¼ôÀ¡ì¸Ç× þÕ §Å¨Ç 
     ¾£Õõ §¿¡ö¸û; §À¡÷ Á¡ó¾õ 
     
 
 
 
 
 
 
 
 
 
 
 
9 
 
BOTANICAL  ASPECT13 
Classification:      
KINGDOM      :Plantae 
CLADE     ;Angiossperms 
CLASS   ;Dicotyledons  
SUB CLASS    :Gameopetalae   
SERIES    ;Inferae 
ORDER   :Rubiales 
FAMILY   :Rubiaceae 
SUBFAMILY  ;Ixoroideae 
TRIBE   :Pavetteae 
GENUS   :Pavetta 
BOTANICAL NAME  :Pavetta indica Linn  
VERNACULAR  NAMES:14 
Benali     :Jui  
Hindi   : Kankara 
Kannada   :Pavati  
Malalayam   :Pavatta  
Sanskrit  :Papata  
Marathi  :Papadi  
 Oriya    :Kotapengu ,kukuchalia 
Telugu     :Paputta vayru 
Tamil   :Pavattai  
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HABITAT:15  
  World –tropical asia, india – common in forests, Is a common shrub found 
 Throughout india, Small stree up to 3mm tall. 
PARTS USED:  
  Root, leaves 
LEAVES:  
  Chartaceous, oblong, obvatvate or lanceolate. 
FLOWER:   
  White in terminal or axillary, trichotomously branched, corymbose cymes  
FRUIT:  
  Berry,  black when ripe 
ACTION AND USES :15 
   The roots are said to posses, purgative, aperients, diuretic, tonic 
properties and are prescribed in jaundice, headache, urinary diseases, and dropsical  
affections a decotion of the root (1in10) is also  Given in doses of ½ to 1 ounce, and with 
ginger  added  in dropsy a decotion of the leaves is used as a lotion for ulcerated nose and 
for Haemorrhoids. 
CHEMICAL CONSTITUENTS : 
It contain a green resin, Starch, an organic acid, Bitter glucoside. 
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Materials and Methods 
Ash Values; 
The Ash values are a measure of the inorganic constituents present in the raw drug.A high 
ash content explains its unsuitable nature to be used as a drug  
Total Ash; 
A little of extract was taken in a silica crucible previously ignited, cooled and weighed.  It 
was incinerated by gradually increasing the heat not exceeding dull red heat (450°C) until 
free from carbon, cooled and weighed. The percentage of ash was calculated with 
reference to air- dried drug. The procedure was repeated to get the constant weight.  
Water soluble ash; 
The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1).  It was followed by washing with hot  water .The  filter paper  was dried  
and  ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble  ash can be calculated by subtracting the water insoluble ash from the total 
ash.  
Acid insoluble ash; 
The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1).  The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed.  
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HPTLC Fingerprint - RH1 
HTPLC of Pavattaiver kudineer Chooranam was done in Ramachandra 
University, Chennai 
Sample Preparation 
100 mg of extract was weighed and dissolved in 70% methanol to get a concentration of 
10mg/ml concentration this is then used for injection.  
Chromatographic Conditions 
Stationary Phase                      : Silica gel 60 F 254   
Mobile Phase                           : chloroform: methanol (9:1) 
Scanning Wavelength               : 404 nm 
Applied volume                       : 10µl 
Development mode                 : Ascending mode 
Significance of HPTLC fingerprinting in Standardisation 
Standardisation of traditional medicine has become mandatory in the present national and 
international scientific scenario, as they have to stand competing with stringent regulatory 
methods and also clinically. HPTLC is one of the versatile chromatographic methods 
presently available for the rapid analysis of herbal drugs due to several reasons. Firstly 
the time required for the demonstration of the most of the characteristic constituents of a 
drug is very quick and short. Secondly, in addition to qualitative detection, HPTLC also 
provides semi-quantitative information on the major active constituents of a drug, thus 
enabling an assessment of drug quality. Thirdly the fingerprint obtained is suitable for 
monitoring the identity and purity of drugs and for detecting adulteration and substitution. 
Hence in order to check the identity, purity and standardise the quantity of active 
principles in the herbal extracts a HPTLC fingerprint of all the 12 ingredient medicinal 
plants used in the formulation has been obtained.       
The distribution of phyto-constituents in a plant depends on various factors such as soil, 
time of collection period of storage, etc. So, it is necessary to standardize the extract 
being used for pharmacological studies. HPTLC serves as a convenient tool for finding 
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out the distribution pattern of phyto constituents which is unique to each plant. The 
HPTLC finger-printing profile establishes the identity and purity of the raw drug being 
used. It helps in the authentification of the plant material.  
Chromatographic Conditions 
The finger printing has been done using the following chromatographic conditions. 
Chromatography was performed on a10x10 cm pre activated HPTLC silica gel 60F 254 
plate. Samples were applied to the plate as 6mm wide band with an automatic TLC 
applicator Linomat 5 with N2 flow (CAMAG, Switzerland), 8mm from the bottom. 
Densitometric scanning was performed on CAMAG scanner III. The plates were pre-
washed by methanol and activated at 600 C for 5 minutes prior to chromatography. The 
slit dimension was kept at 5 minutes x 0.45 minutes and 20 minutes scanning speed was 
employed. The mobile phase was chosen after running each plant in different mobile 
phases of varying polarity (Toluene, Toluene: Ethyl acetate and Ethyl acetate: Methanol) 
and 10 ml of mobile phase was used per chromatography. Linear ascending development 
was carried out in 20 cm x 10-em twin glass chamber saturated with the mobile phase.  
Chromatographic Analysis 
The hydro alcoholic extracts of the plants have been prepared at a concentration of 10 
mg/10 ml in alcohol and were spotted using CAMAG Linomat 5 applicator. The method 
was optimized by selecting appropriate mobile phase for respective plant extracts and 
developed in a twin trough chamber, 20 x 10 cm at 25°C. The plates were dried by hair 
dryer. The developed plates were scanned at appropriate wavelength using CAMAG TLC 
scanner 3 and photo-documented using CAMAG REPROSTAR 3.  
Inferences 
The finger-printing profile establishes the identity and purity of the raw drug being used. 
It helps in the authentication of the respective plant material. The fingerprinting pattern is 
characteristic of each plant material used for pharmacological studies. The pattern clearly 
displays the variation from plant to plant. 
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HPTLC Fingerprint - RH1 
Sample Preparation 
100 mg of extract was weighed and dissolved in 70% methanol to get a concentration of 
10mg/ml concentration this is then used for injection.  
Chromatographic Conditions 
Stationary Phase                      : Silica gel 60 F 254   
Mobile Phase                           : chloroform: methanol (9:1) 
Scanning Wavelength               : 404 nm 
Applied volume                       : 10µl 
Development mode                 : Ascending mode 
Inference  
HPTLC fingerprint of RH -1 shows four peaks at Rf values 0.25, 0.31, 0.41 & 0.95.  The 
peak correspond to the Rf value 0.31 has maximum peak area of 7256.5. At this stage it is 
difficult to confirm the individual components present in the extract, but from our lab 
experience on phytochemical analysis, we suggest that the major peaks found in the 
fingerprint may be acidic glycosides / resins. Since, in the present chromatographic 
conditions, the above mentioned components will be eluted easy.  
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CHROMATOGRAPHIC CONDITION FOR HPTLC FINGER PRINT 
SampleName   :  Pavattatver   kudineer chooranam 
 Sample-ID                   :           107 
Stationary phase :  Silica gel F 254 
Mobile phase  :  n-Hexane: Ethyl acetate: Formic acid   
   (0:40:2.5 ml) 
Scanning wavelength : 254,298,489 nm 
Sample concentration :           20 mg/ml 
Injecting volume :           5, 10 µl  
Development mode :  ascending mode 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
BIO -CHEMICAL ANALYSIS OF PAVATTAIVER KUDINEER CHOORANAM  
 The Biochemical analysis of the Pavattaiver kudineer Chooranam was carried out 
in the Biochemistry lab, NIS. 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample Light brown in 
colour 
 
2. Solubility: 
a.A little(500mg) of the sample was 
shaken well with distilled water. 
b.A little(500mg) of the sample was 
shaken well with con. HCl/Con. H2So4 
 
Sparingly soluble 
 
 
Absence of Silicate 
3. Action of Heat: 
   A small amount (500mg) of the 
sample was taken in a dry test tube and 
heated gartly at first and then strong. 
 
 No white fumes 
evolved  
 
 
Absence of Carbonate 
 
4. Flame Test: 
  A small amount (500mg) of the 
sample was made into a paste with con. 
HCl in a watch glass and introduced 
into non-luminous part of the Bunsen 
flame. 
No Bluish green 
flame appeared. 
Absence of Copper 
17 
 
 
Preparation of Extract: 
5gm of Pavattaiver kudineer Choornam (Pavetta indica)linn   was weighed 
accurately and Placed in a 250ml clean beaker and added with 50ml of distilled water. 
Then it was boiled well for about 10 minutes. Then it was cooled and filtered in a 100ml 
volumetric flask and made up to 100ml with distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1.  Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
 No cloudy 
appearance present 
 
 
  Abesence  
of Sulphate 
 
 
 
2. Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
 No cloudy 
appearance. 
  Absence  
of Chloride 
5. Ash Test: 
   A filter paper was soaked into a 
mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
Yellow colour 
flame appeared. 
Presence of sodium 
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3. Test For Phosphate: 
  2ml of the extract was treated with 2ml 
of dil.ammonium molybdate solution and 
2ml of con.HNo3. 
 Yellow 
appearance present 
   Presence  
of Phosphate 
4 
.  
Test For Carbonate: 
    2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
  Absence  
of carbonate 
5. Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
   Absence  
of Nitrate 
6. Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
   Absence  
of Sulphide 
7. Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No Cloudy 
appearance 
      Absence  
of fluoride and 
oxalate 
8. Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
No Characteristic 
changes 
   Absence  
of Nitrite 
9. Test For Borate: 
  2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
   Absence  
of borate 
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 II. Test For Basic Radicals   
1. Test For Lead: 
        2ml of the extract was added with 
2ml of dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of Lead 
2. Test For Copper: 
a. One pinch(50mg) of substance 
was made into paste with con. HClin a 
watch glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
  Absence  
of copper 
 
 
3. Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
Yellow colour 
appeared. 
  Presence   
of aluminium 
4. Test For Iron: 
a. To the 2ml of extract, 2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
 
blood red colour 
appeared. 
 
 
 
presence of Iron 
 
 
5. Test For Zinc:  
      To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride was 
added.  
 
No White 
precipitate was  
formed 
 
Absence of Zinc 
6. Test For Calcium: 2ml of the extract was 
added with 2ml of 4% dil.ammonium 
oxalate solution  
 No Cloudy 
appearance and 
white precipitate 
 
   Absence  
20 
 
was obtained of calcium 
7. Test For Magnesium:  
    To 2ml of extract dil.sodium hydroxide 
solution was added in drops to excess. 
 
No White 
precipitate was  
obtained 
 
   Absence  
of Magnesium 
8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
 Brown colour 
appeared 
 
     Presence  
 of ammonium 
9. Test For Potassium:  
   A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
 
NoYellowish 
precipitate was 
obtained. 
 
   Absence  
of Potassium 
10. Test For Sodium: 
    2 pinches(50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
 yellow colour 
flame appeared 
    Presence  
of sodium 
11. Test For Mercury:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained 
   Absence  
of mercury 
12. Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
 
No brownwish red 
precipitate was 
obtained 
 
Absence 
of arsenic 
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 III. Miscellaneous   
1.
  
Test For Starch:  
  2ml of extract was treated with weak 
dil.iodine solution  
 
blue colour 
developed 
 
presence 
of starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to 
boil for 2 minutes and added 8 to 10 drops 
of the extract and again boil it for 2 
minutes. The colour changes are noted. 
 
Brick red colour 
developed 
 
presence of  
reducing sugar 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract was treated with  2ml 
of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  
2ml of dil.picric acid. 
c)  2ml of the extract was treated with 2ml 
of dil.phosphotungstic acid. 
 
 
  
Yellow colour 
developed 
 
 
 
   Presence  
of Alkaloid 
4.
  
Test For Tannic Acid:  
  2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
 black precipitate 
was obtained 
   Absence  
of Tannic acid 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution was 
added.  
 
Potassium 
permanganate was 
not decolourised 
 
Absence of 
unsaturated 
compound 
6.
  
Test For Amino Acid: 
 2 drops of the extract was placed on a 
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filter paper and dried well. 20ml of  
Biurette reagent was added. 
colour developed    Absence  
of amino acids 
7. Test For Type Of Compound: 
    2ml of the extract was treated with 2 ml 
of dil.ferric chloride solution.  
No green colour 
developed 
 
No red colour 
developed 
 
 
 
No violet colour 
developed 
 
No blue colour 
developed 
Absence of oxy 
quinole 
pinephrine and 
pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and 
meconic  
acid are absent  
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
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ACUTE AND SUB ACUTE TOXICITY STUDY ON PAVATTAI VER KUDINEER 
CHOORANAM   
Animals 
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute animal ethics committee and obtained from Vels University, Chennai. They were 
fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. The animals were acclimatized for one week 
under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Pavattaiver Kudineer Chooranam was carried out as 
per OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. The 
test substance was administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal is determined and the 
dose is calculated according to the body weight.  
 After the substance has been administered, food was withheld for a further 2 hours 
in mice. The animals were observed continuously for the first 4 h and then each hour for 
the next 24 h and at 6 hourly intervals for the following 48 h after administering of the 
test drug, to observe any death or changes in general behaviour and other physiological 
activities. Single animals are dosed in sequence usually at 48 h intervals. However, the 
time interval between dosing is determined by the onset, duration, and severity of toxic 
signs. Treatment of an animal at the next dose was delayed until one is confident of 
survival of the previously dosed animal.  
Observation of toxicity signs: General behavior, respiratory pattern, cardiovascular 
signs, motor activities, reflexes, change in skin and fur, mortality and the body weight 
changes were monitored daily. The time of onset, intensity, and duration of these signs, if 
any, was recorded.  
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SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex (3+3) rats were 
divided into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were administered 
daily with the Pavattaiver Kudineer Chooranam (p.o.) for 28 days at a dose of 1.0, 2.0 and 
4.0 g/kg respectively. The animals were then observed daily for gross behavioural 
changes and any other signs of subacute toxicity.  
 The weight of each rat was recorded on day 0 and weekly throughout the course 
of the study, food and water consumption per rat was calculated. At the end of the 28 
days they were fasted overnight, each animal was anaesthetized with diethylether, 
following which they were then dissected and blood samples were obtained by cardiac 
puncture into heparinised tubes. The blood sample collected from each rat was 
centrifuged with 3000 X g at 4oC for 10 min to separate the serum and used for the 
biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis glucose, creatinine, total 
protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase 
(ALP)) were automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, Liver, Brain, 
Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all rats to 
visually detect gross lesions, and weighed to determine relative organs’ weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
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embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparison Test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. 
RESULTS 
Clinical signs: Animals were not shown any significant toxic clinical signs during the 
dosing period of 28 days. 
Mortality: All animals from control and all the treated dose groups survived throughout 
the dosing period of 28 days. 
Body weight: Results of body weight determination of animals of control and different 
dose groups exhibited comparable body weight gain throughout the dosing period of 28 
days. 
Food consumption: During dosing period, the quantity of food consumed by animals 
from different dose groups was found to be comparable and normal with that of control 
animals. 
Ophthalmoscopy: Ophthalmoscopic examination of animals in control and test product– 
treated groups did not reveal any major and remarkable abnormality. 
Functional Observations: These tests conducted on the experimental animals at 
termination and recorded did not reveal any abnormalities.  
Urine analysis: Urine analysis data of control group and treated group of animals 
determined in week 4 did not reveal any abnormalities.  
Organ Weight: Comparison of organ weights of treated animals with respective control 
animals on day 28 was found to be comparable.  
Necropsy: Gross pathological examination of animals in control as well as the treated 
groups did not reveal any abnormalities.  
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Haematological investigations: The results of haematological investigations conducted 
on day 28, revealed following significant changes in the values of different parameters 
investigated when compared with those of respective controls; However, the increase or 
decrease in the values obtained was within normal biological and laboratory limits.  
Biochemical Investigations: Results of Biochemical investigations conducted on days 29 
revealed significant changes in the values of uric acid and potassium studied when 
compared with those of respective controls; however, the values obtained were within 
normal biological and laboratory limits.  
CONCLUSION: 
 Based on these findings, no toxic effect was observed upto 500mg/kg of Pavattai 
ver kudineer chooranam treated via oral route over a period of 28 days. So, it can be 
concluded that the Pavattaiver kudineer chooranam can be prescribed for therapeutic use 
in human with the dosage recommendations of upto 500mg/kg. body weight p.o. 
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HEPATOPROTECTIVE ACTIVITY OF PAVATTAI VER KUDINEER 
CHOORANAM AGAINST ALCOHOL INDUCED IN ALBINO RATS 
 
INTRODUCTION 
 Liver diseases have become one of the major causes of morbidity and mortality all 
over world. In spite of tremendous advances in modem medicine, there are hardly any 
reliable drugs that protect the liver from damage and/or help in regeneration of hepatic 
cell. Many active plant derived products are frequently utilized to treat a wide variety of 
clinical diseases including liver disease. Therefore, searching for effective and safe drugs 
for liver disorders are continues to be an area of interest. The liver is one of the few 
organs of highly specialized function whose cells can undergo an astonishing degree of 
regeneration. Modern allopathic treatment does not hold promise to cure liver disease 
perfectly.  
 A number of medicinal plants are used in traditional system of medicine for the 
management of liver disorders. Liver disease is still a worldwide health problem. 
Unfortunately, conventional or synthetic drugs used in the treatment of liver diseases are 
inadequate and sometimes can have serious side effects1. In the absence of a reliable liver 
protective drug in modern medicine there are a number of other herbal preparations to 
treat successfully liver diseases remain one of the serious health problems.   
 In view of severe undesirable side effects of synthetic agents, there is growing 
focus to follow systematic research methodology and hence the auther intake to evaluate 
scientific basis for the traditional siddha medicines like Pavattaiver Kudineer Chooranam 
that are claimed to possess hepatoprotective activity.  
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MATERIALS AND METHODS 
Animals 
 In this experiments thirty healthy male albino Wistar strains rats, 3 months of age, 
weighing 240–258 g were selected for acclimation for a period of two weeks in laboratory 
animal house and maintained under standard conditions of temperature 27 ± 20C, relative 
humidity of 60 ± 5% and 12: 12 hour light: dark cycle prior to experimentation. They 
were given standard pellet diet (Sai durga foods Ltd. Bangalore) and tap water ad libitum. 
The experiments were performed during day (08:00-16:00 h). The institutional animal 
ethical committee had approved to the study protocol. 
(XIII/VELS/PCOL/30/2000/CPCSEA/IAEC/08.08.2012).  
Experimental Design 
 The animals were fed with standard pellet diet and water ad libitum. The 
experimental animals were divided into five groups each contains six animals as per the 
drug treatment plan. First group served as normal control and the rest served as 
experimental groups. 
GROUP I: Normal control (n=6, the animals were given normal saline only) 
GROUP II: Hepatotoxic control, the animals were given ethanol 50% 12ml/kg for 21 
Days) 
GROUP III: Treatment group (n=6, the animals were given alcohol + Pavattaiver 
Kudineer Chooranam 250mg/kg for 21 days) 
GROUP IV: Treatment group (n=6, the animals were given alcohol + Pavattaiver 
Kudineer Chooranam 500mg/kg for 21 days) 
GROUP V: Standard group, the animals were given alcohol +Silymarin (25 mg/kg) 
for21 days)  Rats were treated as per the treatment protocol. Body weights of these rats 
were monitoredsequentially in control and experimental animals for a period of 21 days. 
After collection of the blood, the liver was removed and washed several times with 
normal saline. Part of the liver was taken for biochemical estimations and the remaining 
tissue was preserved in 10%v/v formal saline buffer for histopathological analysis.  
Biochemical Assays 
 At the end of the drug treatment period, all the animals were anaesthetized by 
application of light chloroform and blood samples were collected from a group of animals 
from dorsal aorta by heparinized syringe in vacutainer tubes. Plasma and serum samples 
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were separated kept at – 20˚C for biochemical analysis. The animals were sacrificed by 
cervical decapitation, the perfused liver of each animal was dissected out and washed 
with isotonic solution, and their wet weight was recorded. The liver homogenate was 
prepared using phosphate buffer solution for biochemical analysis. The biochemical 
parameters analyzed from serum, plasma and liver homogenate are  presented in the 
Graph.  
Histopathological studies 
 After treatment, liver of all animals from each respective groups were dissected 
out and a portion of liver tissue section of nearly 5 μm thickness were fixed in Bouin’s 
fixative, dehydrated by varying percentage of ethanol and stained with haemotoxylin and 
eosin. Histopathological examination of the liver sample was carried out by taking thin 
transverse section with the help of microtome and permanent slides were prepared. The 
slides were examined under microscope. Histology of normal liver, damaged liver and 
recovered liver was studied and compared. 
Statistical analysis 
 The data was represented as mean ± S.E.M. Results were analyzed statistically by 
one-way ANOVA followed by Dunnett's multiple comparison test using Prism software 
(Version 4). The minimum level of significance was set at P < 0.05. 
 
RESULTS AND DISCUSSION 
 The acute toxicity study revealed the absence of lethality among the tested 
animals when the Pavattaiver Kudineer Chooranam was administered as a single dose 
(2000, 5000 mg/kg). There were no signs of any gross behavioral changes indicating the 
safe use of the Pavattaiver Kudineer Chooranam. The result of the biochemical tests 
revealed the elevation of serum enzyme level in alcohol treated group compared to 
control group, indicating that alcohol induced liver damage. A significant reduction was 
observed in SGPT, SGOT levels in the group treated with Pavattaiver Kudineer 
Chooranam.  
 The ALP and bilirubin in serum was significantly (P <0.01) increased in alcohol 
treated animals when compared to control. The Pavattaiver Kudineer Chooranam 
treatments significantly (P<0.01) reversed the levels of AST, ALP and bilirubin alcohol 
treated rats. Normally, AST and ALP are present in high concentration in liver. Due to 
hepatocyte necrosis or abnormal membrane permeability, these enzymes are released 
from the cells and their levels in the blood increases. ALT is a sensitive indicator of acute 
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liver damage and elevation of this enzyme in non hepatic diseases is unusual. ALT is 
more selectively a liver paranchymal enzyme than AST.  
Assessment of liver function can be made by estimating the activities of serum ALT, 
AST, ALP and Bilirubin which are enzymes originally present higher concentration in  
cytoplasm.When there is hepatopathy, these enzymes leak into the blood stream   in 
conformity with the extent of liver damage. The elevated level of these entire marker 
enzymes observed in the group II, alcohol treated rats in this present study corresponded 
to the extensive liver damage induced by toxin. The reduced concentrations of ALT, AST 
and ALP as a result of Pavattaiver Kudineer Chooranam administration observed during 
the present study might probably be due in part to the presence of active principles like 
flavonoids, alkaloids and tannins. Bilirubin is one of the most useful clinical clues to the 
severity of necrosis and its accumulation is a measure of binding, conjugation and 
excretory capacity of hypatocyte. Silymarin (25 mg/kg) treated animals also showed 
significant decrease in AST (P<0.01), ALT, ALP and bilirubin (P<0.01) levels when 
compared to the treated with alcohol alone rats. A comparison of the liver section of 
animals treated with ethanol showed a high degree of damage characterized by cell 
vacuolation, pyknotic and degenerated nuclei and wall of bile capillaries.  
 The normal architecture of the liver was lost. The intralobular vein was badly 
damaged with wide spaces at some sinusoids. In the liver section of the animals treated 
with Pavattai Ver Kudineer Chooranam (250 and 500mg/kg b.w.) + ethanol, the number 
of hepatocytes with normal nucleus was clearly appeared. Liver is a versatile organ in the 
body concerned with regulation of internal chemical environment. Therefore, damage to 
the liver inflicted by hepatotoxic agents is of grave consequence. It was observed from 
the morphological examination of liver that treatment with alcohol resulted in liver 
enlargement, which turned pale brown in colour. The hepatic cells of rats treated with 
Pavattaiver Kudineer Chooranam (250 mg/kg b.w.) and intoxicated with ethanol were 
radially arranged. The vacuolation was present, similar to that of normal.  
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The recovery was comparable to that with silymarin, a standard hepatoprotective agent 
The intralobular vein was normal in structure, but the wall was damaged. No pyknosis in 
the nucleus was seen. In general, alcohol caused marked damage of rat hepatocytes in the 
form of fatty degeneration, cytoplasmic vacuolation, centrilobular necrosis, ballooning 
degeneration, nodal formation and fibrosis with endothelial swelling and disruption. The 
histopathological studies are the evidence of efficacy of drug Pavattaiver Kudineer 
Chooranam as liver protectant.  
Treatment of Pavattaiver Kudineer Chooranam with alcohol exhibits less damage to the 
hepatic cells as compared to the rats treated with pure alcohol alone. The sections of the 
liver treated with Pavattaiver Kudineer Chooranam and alcohol reveals better 
hepatoprotective activity. Hence, the results of histopathological study also support the 
results of biochemical parameters.  
CONCLUSION 
 The acute toxicity study revealed there were no signs of any gross behavioral 
changes indicating the safe use upto 5g/kg in mice. Decrease in serum bilirubin after 
treatment with the Pavattaiver Kudineer Chooranam in liver damage induced by alcohol, 
indicated the effectiveness in normal functional status of the liver. The normal cellular 
architecture was retained as compared to silymarin, thereby confirming the protective 
effect of the Pavattaiver Kudineer Chooranam.  
 In accordance with these results, it may be hypothesized that active principles,of 
the drug could be considered responsible for the hepatoprotective activity. The 
Pavattaiver Kudineer Chooranam has shown the ability to maintain the normal functional 
status of the liver. From the above study, it can be concluded that the Pavattaiver 
Kudineer Chooranam, is proved to be one of the better remedy for liver ailment. 
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     DISEASE ASPECT 
SIDDHA ASPECT:           
    fšäuš nehŒfŸ7  
ntWbga® : ty¥ gh£Ouš nehŒ, khªj¡ f£o, fškhªj«, 
 a¡Fj« vd¥ bga®fS©L. 
ïašò:  
ïa‰ifahf kh®ã‹ Ñœ ty¥g¡f« cŸs ty¥gh£Ouš, m¥g¡fKŸs 
filÉyh vY«ò tiuÆY« Ã‰fhkš j‹dsÉš nkY§ÑGkhf¥ 
bgU¤J¡bfh©nl tUtJ«, j‹ ïa‰if¤ bjhÊiy ïH¥gJ«, mšyJ msÉš 
Äf¢áW¤J¡ bfh©nl tªJ gy nehŒfisí« Jizah¡FtJkhd ïašig¥ 
bgW« nehah«. 
nehŒ tU« tÊ 
ÄFªj msÉš czití©zš, cl‰bfh›th¥ bghUŸfis¡ 
bfhŸsš, fŸ, rhuha«, KjÈa ka¡f¤ij¤ jU« Fo tiffis msî flªJ 
Fo¤jš, bg©fË‹ T£lhš tU« nehŒ M»at‰whY«, Ru« KjÈa 
nehŒf£L¡F¤ Jizahfî« tUtjhF«. m‹¿í« áW FHªijf£F« ghš, 
czî KjÈa ntWghLfshY« tUtJ©L. 
K‰F¿: 
thŒ if¤jš, RitÆ‹ik, thŒ ÚUwš, gáÆ‹ik, c©l czî 
brÇahik, fhiyÆš ã¤jkhf thªâahjš, Kf« RU§» KfvY«ò 
vL¤J¡fh£lš, if fhš N«ã tÆW eh£FehŸ bgU¤J¡ bfh©nl tUjš, 
mo¡fo Ru§fhŒjš v‹D« F¿fis¡ fh£o ty¥gh£Ouš bgU¤J¡ bfh©nl 
tU«. 
nehŒ v©: 
F‰w msthf _‹W tif¥gL«. mit tË¡ fšäuš 
nehŒ, mHš fšäuš nehŒ, Ia¡ fšäuš nehah«. 
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F¿ Fz§fŸ 
tË¡fšäuš nehŒ: 
clÈ‹ f© tË¡ F‰w« bgU»¤ jd¡F¤ Jizahf mHš 
F‰w¤ijí§ T£o, Ru¤ijí©lh¡», cliy ehS¡F ehŸ, ïis¡f¢ brŒjš, 
clš fUÃwkhjš, clš t‹ik Fiwjš, tÆW bgU¤J¡ bfh©nl tUjš, 
ïur ehs§fË‹ Ko¢RfŸ fd¤J¤ bjhil ïL¡FfËY«, m¡FŸ, tÆW, 
fG¤J, kh®ò ït‰¿š njh‹wš v‹D§ F¿fis¡ fh£o, eh£ bršy¢ bršy¥ 
gL¡ifÆÈU¤â¤ J‹òW¤J«. nehŒ Kâa§fhiyÆš clÈ‹ FUâ FiwªJ 
clš btS¤J¡ fhš, if, tÆW M»atiffS« å§»¡fhQ«. 
mHš fšäuš nehŒ: 
ïjÅš mHš F‰wnk jÅ¤J©lhd nehahjyhš, mHš F‰w¤ 
âdsthf¥ ãwªj FUâbf£L, fšäuÈš ïa‰if¢ braY§ F‹¿¥ ã¤JÚiu 
clš KGikí« åá cliy kŠrŸ Ãwkh¡F«. m‹¿í« thŒ if¤jš, ã¤J 
thªâahjš, KfŠ RU§fš, if fhš å§fš, FUâÆ‹ t‹ikÆ‹ikahš clš 
btS¤J¡fhzš v‹D§ F¿fis¡ fh£o, bgU tÆWnehiaí« ã‹ bjhlu¢ 
brŒí«. 
Ia¡fšäuš nehŒ: 
ïa‰ifahf, ïªnehÆš ÄFªj mHš F‰w¤njhL Ia¡F‰wK§ TotU 
nehahifahš, fšäuš Äf¥ bgU¤J, bjhLif¡F¡ f£o K£oahf¡ fhz¥gL«. 
m‹¿í« fšäuÈ‹ bgU¡f¤ijí« mjÅ‹ nkbyGªj vG¢áÆ‹ toití« 
fhzyh«. <uÈ‹ bgU¡f¤â‰nf‰g, ÄFªj RuK«, thªâí« jiynehí«, 
mo¡fo fÊjY«, áWÚ® átªJ, msÉš FiwªJ ïÊtJkhd F¿ Fz§fnshL, 
kŠrŸ (fhkhiy) nehŒ, clš å§Fjš, clš btS¤jš M»a nehŒfS« 
Jiz¡bfh©L bgU tÆW nehŒ bjhlUtJ« c©L. 
nehŒ, Cjš (nrhif) nehŒ, bgUtÆW nehŒ M»a ïªeh‹F« 
x‹w‹ã‹ x‹whf¤ bjhlUtJ ïašgh«. 
fšäuš nehŒ mHš F‰w¤â‹ bgU¡fhš tUnehahjyhY« ïªnehŒfËš 
vªnehŒ K‹ ãw¥ãD« mjid¥ g‰¿na k‰wJ« bjhlUkhifahY« ï›ÉU 
nehŒ¡F« k‰w KjÈa ntWghLfŸ x‹Wg£nl fhz¥gL«    
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F‰w ntWghL 
ïªnehŒ mHš (ã¤j) F‰w¤jhbyGªJ jd¡F¤Jizahf k‰w ïU 
F‰w§fis¡ T£o¡ bfh©L guîfhÈ‹ braiy¡ bfL¤J tUnehah«. 
mHš F‰wnk j‹dsÉš bfLkhifahš cl‰f£LfËš ïurK«, 
FUâí« t‹ikÆHªJ clšt‰¿¥nghjY«, fÊ¢rš thªâí©lhtJ«, ã¤JÚ® 
ïa‰if tÊ bršyhjjhYK©lhd bfLjšfis¥ ãw¥ã¡F«. 
clyikíÄ¡nfLfshš, Ñœneh¡F¡fhš, nkšneh¡F¡fhš M»a 
ï›Éu©L§ To nehia¥ bgU¡F«. 
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MODERN  ASPECT 
ALCOHOLIC  LIVER  DISEASE:16 
Chronic and excessive alcohol ingestion is one of the major causes of liver  diseases, each 
time liver filters alcohol some of the liver cells die, liver can develop new cells, but 
prolonged alcohol misuse over many years can seriously damage the liver and is the cause 
of  Alcoholic Liver Diseases. 
ETIOLOGY:  
               Quantity and duration of alcohol intake are the most important risk factors   
involved in the development of  Alcoholic Liver Diseases. Severe alcoholic in men is an 
intake of>60 to80g/d of alcohol for 10 years, While women are at increased risk for 
developing Similar  Degree of liver  injury by consuming 20 to 40 g/d . 
 
COMMON SYMPTOMS:  
   Dry mouth 
   Fatigue  
   Nausea  
   Loss of appetite  
   Pain in the abdomen  
   Weight loss  
   Enlarged liver  
   Jaundice  
STAGES OF ALCOHOLIC LIVER DISEASES: 16 
There are three main stages of ALD although, there is often on, overlab between each 
stage.  
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ALCOHOLIC  FATTY LIVER DISEASES:  
Drinking of large amount of alcohol even for only a few days,can Lead to a build up of 
fatty acids in the liver. 
ALCOHOLIC  HEPATITIS:  
Alcoholic hepatitis is second more serious stage of ALD, prolonged alcohol misuses over 
many years, can cause the tissues of the  liver to become inflamed.this  is known as 
alcoholic hepatitis.  
CIRRHOSIS:  
Cirrhosis is the final stage of ALD cirrhosis happens when prolonged inflammation 
causes scarring of the liver and loss of function. 
PATHOLOGY:  
The liver has a limited repertoire in response to injury,fatty liver is the initial and 
most common histologic response to hepatotoxic stimuli,including excessive alcohol 
ingestion.the  Accumulation of  fat with in the perivenular hepatocytes coincides with the 
location of alcohol dehydrogenase,the major enzyme renponsible for alcohol  metabolism  
COMPLICATIONS:17  
Complication of alcoholic liver disease include  
· Portal hypertension  
· Hepatic encephalopathy 
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INVESTIGATION:18  
· Complete blood test 
· Liver function test  
· Abdominal CT scan  
· USG abdomen  
· Liver biopsy  
 
TREATMENT: 
  The most important part of treatment is to stop using alcohol completely, if 
liver Cirrhosis has not yet occurred the liver can heal  itself . 
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CLINICAL STUDY 
The study was conducted on patients with Kalleeral noi (Alcoholic Liver  
Diseases) Patients Satisfying the inclusion criteria. The study  was conducted at the 
OPD/IPD of Ayothidoss Pandithar Hospital of the National Institute of Siddha, 
Tambaram sanatorium, Chennai-47. 
Sample size:  
The trial size was 20 patients. 
Inclusion criteria: 
 Age  : 20 to 60 years 
 Sex  : Male 
 Symptoms:  
· Anorexia  
· Malaise 
· Nausea 
· Vomiting 
· Upper abdominal pain  
· Jaundice 
Patient who are willing to provide blood for lab investigation   Patient willing to 
sign the informed consent starting that he/she will  conscientiously  Stick to the treatment, 
during 30 days but can opt out of the trial of His/her own Conscious discretion.  
Exclusion criteria: 
   Cardiac diseases 
   Hepatic failure  
   Pregnancy and laction 
   Any other serious illness  
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Withdrawal criteria:  
   Development of any adverse reaction 
   Occurance of any other serious illness 
   Non-co operation of the patient  
 
TRIAL DRUG AND DURATION 
Drug;    :Pavattaiver  kudineer chooranam 50gm, bd (50ml)  
     After a food 
           
Duration of the treatment: 30 days. 
Conduct of the study: 
Kalleeral noi patients satisfying inclusion and exclusion criteria were admitted to 
the Ttrial. Informed consent was obtained from the patients. Routine investigations like 
Blood test, Uurine Test, were carried out before and after the trial treatment. For in 
patients the drug was  
Administered daily. For out patients the trial drug was issued for seven days 
course. They were advised to visit the OPD once in 7 days. At each visit they were 
clinically assessed.  
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Clinical observation: 
For the clinical study of “Pavattaiver kudineer Chooranam’’ on Kalleeral noi. 20 
male patients were selected.   
Among 20 patients were in male.  
According to age wise distribution 20%were in 20-30years,30 % were in 31-
40years and  50% were in 41-60 years. 
Among 20 patients, All patients were affected from Anorexia, 17  patients were 
affected From Malaise,  16 patients were affected from Nausea, 15 patients were affected 
from Vomiting,16 Patients were affected from upper Abdominal pain, and 7 patients were 
suffering From jaundice. 
From the clinical study 85% of patients relieved from Anorexia, 76.48% of 
patients Relieved from Malaise, 68.75% of patients relieved from Nausea, 80% of 
patients relieved from Vomiting, 75% of patients relieved upper Abdominal pain, 57.15% 
of patients relieved from Jaundice and no adverse effects were observed during trial 
period.  
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DISCUSSION 
 
 The principle aim of this study was to assess the pre-clinical safety and efficacy 
and to Evaluate the therapeutic efficacy of the drug Pavattaiver Kudineer Chooranam  in 
the Management of kalleeral noi. 
 As per Siddha text, in Kalleeral noi vathaa and pitha humors were deranged. 
Vatha thathu is responsible for the functioning of the Udal thathukal uniformly. Hence 
derangement of the Vatha kutram leads to impairment in Udal thathukal and in turn 
produces symptoms like Tiredness, body ache, mental distress etc. 
 Pitha thathu has the basic function of production and maintenance of the blood 
Environment and also for appetite and proper digestion of foods. Hence Pitha thathu 
when Deranged produces symptoms like nausea, vomiting. 
 The trial drug Pavattaiver Kudineer Chooranam possess kaippu, kaarppu suvai 
and kaippu Suvai hence it balances the deranged pittha kutram. In addition to this it also 
have Stomachic Activity which rectifies the symptoms present in Kalleeral noi like pasi 
inmai, suvai inmai. 
 Hence administration of the trial drug pavattaiver kudineer chooranam was 
effective in the management of Kalleeral noi. 
 Role of Alkaloid19 in treating alcoholic liver disease. It possesses anti-oxidant 
property and Causes induction of anti-oxidant enzymes like Superoxide dismutase and 
reduces glutathione & Catalase.  
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Toxicological studies: 
Acute oral toxicity study:  
Based on these findings,no toxic effect was observed upto 5000mg/kg of Pavattaiver 
Kudineer  Chooranam treated via oral route over a period of 28days. the dose of 
5000mg/kg did not exhibit any mortality in rats. As per OECD 425 guidelines. 
 Pharmacological studies: 
In the pharmacological studies the drug Pavattaiver kudineer chooranam exhibits 
significant Hepatoprotective activity.   
Clinical observation:  
From the clinical study 16 (80%) patients had a significant reduction in the LFT 
levels after the treatment. 
Bio-statistics: 
              Statistically, the paired‘t’ test shows statistical significance for the symptoms 
before and after the treatment (p<0.0001). 
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SIDDHA ASPECT: 
À¡Åð¨¼§Å÷:  
Í¨Å  : ¨¸ôÒ, ¸¡÷ôÒ  
¾ý¨Á :   ¦ÅôÀõ, 
À¢Ã¢×  :  ¸¡÷ôÒ. 
¨¸ôÒ Í¨ÅÂ¢ý ¾ý¨Á, 
   Å¡ö¿£ÕÈø «Æüº¢Ôõ ¾½¢ìÌõ." 
fšäuš nehö mHš F‰w¤â‹ bgU¡fhš tUnehahjyhY« mjid¥  g‰¿na 
k‰wJ« bjhlU«, ¨¸ôÒ Í¨Å À¢ò¾ ÌüÈò¨¾ ºÁÀÎòÐõ ±ýÀ¾¡ø fšäuš 
§¿¡ö¸¨Çô §À¡ìÌõ  ¾ý¨ÁÔûÇÐ.25 ¦ÅôÀ Å£Ã¢Âò¾¢ý ¾ý¨ÁÂ¡ÉÐ Å¡¾ò¨¾ 
ºÁôÀÎòÐõ ±ýÀ¾¡ø, þ¨¾  fšäuš  nehöìÌ ÅÆí¸Ä¡õ.  
Hence, pavattaiver kudineer chooranam is a better drug of choice in the management of 
kalleeral Noi 
 
 
 
 
 
 
 
 
 
 
46 
 
SUMMARY 
The literary evidence strongly support the Hepatoprotective activity of Pavattaiver 
Kudineer choornam. The drug Pavattaiver has been selected for this study to evaluate its  
efficacy on the  Hepatoprotective activity in the management of Kalleeral noi (Alcoholic 
Liver Disease ). 
Biochemical analysis of the drug Pavattaiver kudineer choornam reveals the 
presence of, Iron, phosphate, alluminum, starch, sodium, alkaloids, reducing sugars 
and ammonia. 
The Preclinical evalution (acute oral toxicity study) of the drug was carried out as 
per OECD 425 guideline in Vels College of pharmacy, Chennai. The result shows safty of 
the drug for human administration 
In the toxicological studies, the drug does not exhibit any mortality upto the dose 
of 5000mg/kg/po. In the pharmacological studies the drug Pavattaiver kudineer 
chooranam exihibits significant hepatoprotective activity.  
From the clinical study 85% of patients relieved from Anorexia, 76.48% of 
patients relieved from Malaise, 68.75% of patients relieved from Nausea, 80% of patients 
relieved from vomiting, 75% of patients relieved upper Abdominal pain, 57.15% of 
patients relieved from Jaundice and no adverse effects were observed during trial period. 
 From the statistical analysis-paired ‘t’ test, the drug pavattaiver kudineer 
Chooranam is satistically significant. 
Statistically, the paired ‘t’ test shows statistical significance for  symptoms before 
and after the treatment.(p<0.0001) 
The drug Pavattaiver kudineer Chooranam has 
§ Hepatoprotective Activity. 
§ No side effects 
§ No undoing effects 
§ Encouraging clinical results.  
From the clinical and statistical analysis it is proved that the drug pavattaiver 
kudineer chooranam is statistically significant on Hepatoprotective activity, in the 
management of Kalleeral Noi (Aalcoholic Liver Disease) 
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CONCLUSION 
   From the literary evidences, phytochemical review and bio chemical, 
toxicological and pharmacological studies, it is concluded that drug Pavattaiver kudineer 
chooranam has significant Hepatoprotectiv Activity. Thus it gives a new hope in the 
management of Kalleeral Noi (Alcoholic Liver Disease). 
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INTRODUCTION    
Kaanakadi (urticaria):20 
Hives, neetle rash is a common skin condition characterized by the acute 
development of the itchy weals or swellings in the skin. Because of leaky dermal vessels, 
Urticaria is described as acute it last less than 6 weeks, and chronic if it persists beyond 
this.  
Prevalence:21  
Approximately 15% of people experiance urticaria at some times in the lives the  
prevalence rate has been assessed as 1-5 per 1000,   Chronic urticaria occurs in at least 
0.1% and Possibily  up to 3% of the population. Chronic urticaria is twice as common in 
women as in men. 
In Indian study showed that out of 500 cases of urticaria 37% were suffering from 
physical urticaria22  
              In siddha system of medicine the urticaria can be clinically compared with 
Kaanakadi.Gandhaga Maathirai is a Herbo mineral formulation mentioned Anuboga 
vaithiya Nava Needham  part 6, The ingredients of this formula are Gandhagam and 
Changan (Azima tetracantha)Lam. leaves  
As per siddha text the drug gandhagam has kaippu and thuvarppu suvai, changan has 
kaippu suvai as per the siddha principle the kaippu and thuvarppu suvai are very effective 
for skin disease Like kaanakadi Kaippu suvai has antidote and thuvarppu suvai has blood 
purification action.23 the previous studies report showed that Azima tetracantha has 
antifungal24, antimicrobials25, antibacterial26, and wound healing properties25. 
Gandhaga maathirai has not been evauvated for H1 histamine antagonistic activity 
on kaanakadi Based on the literature evidence hence the researcher has selected the 
Gandhaga Maathirai, for H1 histamine antagonistic activity and therapeutic efficacy on 
kaanakadi.  
 
 
49 
 
AIM: 
 To evaluate the safety and efficacy of Gandhaga Maathirai for H1-histamine 
antagonist Activity on Kaanakadi (Urticaria). 
OBJECTIVE: 
Primary objective: 
To evaluate the H1-Histamine Antagonistic activity of Gandhaga Maathirai for 
Kaanakadi (Urticaria). 
Secondary objective: 
 To evaluate the efficacy of Gandhaga Maathirai in the management of Kaanakadi 
(Urticaria). 
 1. Collection of evidences in siddha literature. 
 2. Collection of evidences in botanical aspects. 
 3 .Standard operative procedure  
4. Biochemical analysis  
 5. Physical properties   
 6. Atomic Absorption Spectrophotometer 
 7. Pharmacological study    
 8. Clinical study A pilot study on trail medicine 
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MATERIALS AND METHODS     
STANDARD OPERATIVE PROCEDURE 
Collection of the raw drug: 
 The raw drug was collected from The from Ramasamy chetty shop paris Chennai, 
and During in chennai. Authenticated by competent in department of gunapadam.  
Purification process:  
Purification of Gandhagam 
 Gandhagam was purified by Thooma pudam using cow’s milk for 3 times27  
Preparation of the test drug:   
The purified Gandhagam was grinded in to tiny particles and Soaked in juice of 
Changan Leave (Azima tetracantha). which  placed in the sun light, And have to be dried, 
The dried Gandahagam, soaked in that juice Again.This process is repeated for 30 times, 
and Grinded in the Kalvam, made in to tablet in the size of kundri (130mg). The tablet is 
dried in the sun shadow.  
 LABELLING: 
Name of the preparation    : Gandhaga Maathirai 
Colour                : Mild green colour 
Dose                   : 130 mg b.d. 
Adjuvant                : Palm jaggery 
Duration                : 40 days 
 Indication                 :  Kaanakadi 
 Date of manufacture         : The drug was prepared in two batches.  10/3/12,  15/5/12     
 Expiry                    : 1year  from the date of manufacture  
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     GANDHAGAM  BEFORE PURIFICATION                   
 
          
         
   PURIFIED GANDHAGAM 
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Azima tetracantha (Lam) 
 
 
 
   GANDHAGA MAATHIRAI 
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RVIEW OF THE LITERATURE 
GUNAPADAM ASPECT 
fªjf«   
fªjf«28   
ï¥bghUŸ fhÇiHÆ‹  ehj«, giu,  åÇa«,  mÔj¥ ãufhr«,  
Õ#«,  bršÉÉªJ,  r¡â,  r¤âÕr«,  brªöu¤jhâ,  jd«,  njÉíu«,  
ehj«, eh‰w«, giu ehj«, bgh‹t®Â, ïur RnuhÂj« v‹w ntW 
bga®fËdhY« tH§f¥gL»‹wJ. 
ghlhz§fŸ mWg¤J eh‹»š,  
· ãw¥ò¡ fªjf«, 
· it¥ò¡ fªjf«,   
· nfhÊ¤jiy¡ bfªâ it¥ò, 
· thzbfªâ it¥ò  
v‹W eh‹F ghlhz§fŸ Tw¥g£LŸsd. ït‰WŸ K‰Tw¥g£l x‹W 
kiyÆ‹ ãw¡»‹w ru¡fhF«. ã‹nd Tw¥g£l _‹W« ãw¥ò¡fªâÆid 
Kj‹ikahŒ¡ bfh©L k‰iwaru¡FfË‹ cjÉahš brŒa¥gL»‹w 
ru¡FfshF«. nfhÊ¤jiy¡ bfªâÆ‹ Ãw« kh¤âu«,  N£o‹ Ãw« v‹W 
F¿¥ãl¥g£LŸsJ k‰W« bfªjf« ngj« TWÄl¤J, ehštif T¿ ehštif¢ 
rhâ¡bfh¥ã£L, mitfË‹ ÃwK« gyD« Tw¥g£LŸsd. 
1. bt©ik Ãw¤ijíilaJ; všyh nehŒfisí« Ô®¡F«. 
2. »Ë _¡F¢ át¥ò Ãw¤ijíilaJ. etnyhf¤ij Vkkh¡F«. 
3. bgh‹ik ÃwKilaJ; F‰wk‰w bešÈ¡fhŒ ngh‹W ïU¡F«; 
Njf¤njhL cwth»¢ R¤jkhŒ ïU¡F« 
4. fhf¤â‹ Ãw¤ijíilaJ; mf¥ghlhJ; mf¥g£lhš eiu âiufŸ 
m‰W¥ngh«. 
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Ã‰f, gjh®¤j Fz áªjhkÂÆš bešÈ¡fhŒ¡ fªjf«, thz fªjf« ïitfË‹ 
Fz§fŸ kh¤âu« Tw¥g£oU¡»‹wd. MÆD«, kUªJfËš ifahs¥gLtJ 
bešÈ¡fhŒ¡ fªjfnk ahF« v‹W cz®f. 
neghs«,fhZÛ®,M¥fhÅ°jhd«, g®kh KjÈa ïl§fËš fªjf« »il¡»‹wJ. 
jhJ jhtu ét¥ bghUŸfËY« ïJ fy¥ò‰¿U¡»‹wJ. 
 k‰W«, “brhšYnk jh«ãu¤ij¡ bfªâ bfhšY«” “fªâ¡»dK Äurªjh 
bd‹whnu” v‹w tofshš ïj‹ gifiaí« e£igí« m¿ayh«, 
“brªöu¤jd¡fhâ áiy bfªâ jhsfK«” v‹w moahš, brªöu« 
brŒtj‰F¡ fªjf« cgnahfkh« v‹gjidí« cz®f. 
 
Rit, brŒif, Fz« 
ïjDila bganu  ïj‰F kzK©bl‹gij És¡F«.  
fªjf«, if¥ò¢ Ritiaí«, Jt®¥ò¢ Ritiaí« cilaJ.  ïj‰F¥ ã¤jÚiu 
mâf¥gL¤J« brŒifí«,  kyÄs¡»¢ brŒifí«,  clš nj‰¿, Éa®it 
bgU¡»,  »UÄehrÅ M»a brŒiffS« c©L. á¿a  msÉš fªjf¤ij 
cŸS¡F mUªj m~J cl«ãš nr®ªJ Éa®it, ghš, áWÚ®, ït‰¿‹ thÆyhf 
btË¥gLtij¡ fhzyh«. njhš, mRf§fË‹ rË¢ r›ÉYŸs nfhs§fË‹ 
Ru¥ig mâf¥gL¤J«. Énu»Æš áw¥ghf¢ brašg£L Ru¥ig mâf¥gL¤J«. 
fªjf¤ij, mâf msÉš mUªj¥ ngâia c©L g©Q«. 
 Ñœ¢ brŒí£fshš fªjf§fË‹ bghJ¡ Fz¤ij cz®f. bešÈ¡fhŒ¡ 
fªjf¤â‹ Fz«  
  “bešÈ¡fhŒ¡ fªâ¡F ÚŸgâbd© F£lkªj« 
  tšiy fÉirF‹k thíf©nzhŒ - bghšyh 
  Él¡fot‹ nkfnehŒ åWRu« ngâ 
âl¡»uf Ùfg« nghª nj®” 
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(bghUŸ) bešÈ¡fhŒ¡ fªjf¤âdhš gâbd©F£l«, kªj«, fšäuš, 
å¡f«, bgUtÆW tiffSŸ x‹wh»a fÉir, F‹kthí, f©nzhŒfŸ 
bfhLikia¢ brŒ»‹w Él¡fofŸ, eh£g£l nkf nehŒfŸ, thj Ru«, ngâ, 
eh£g£l »ufÂ, fg« KjÈad Ú§F« . 
thz¡ fªjf¤â‹ Fz« 
“thz¡ FHhŒ¡fªâ thridia¡ f©lîl‹  
fhz¡ »UÄ brh¿ fhzhth« - njhQ« 
bgUÉah â¡T£l« ngUkj }È‹ 
kUÉah G§bfhona thœ¤J” 
 (bghUŸ) thz kUªJ¡fhd FHhŒ¡ fªjf¤â‹ thridia¡ f©lîl‹ 
ïur ïu¤j jhJ¡fËš ãwªj »UÄfŸ, brh¿, FiwnehŒ¡ F£l§fŸ Ú§Fbk‹g 
k‰W« ïjid, eh£g£l Ñš thj«, Rthrfhr«, khuil¥ò, ïUkš, f©lkhiy, 
_y«, Fj be»œ¢á ngh‹w nehŒfS¡F« cgnah»¥gJ©L. 
fªjf«, jhŒ kfit ts®¥gJ nghy nehŒfË‹ bt¥g¤ij kh‰¿ 
cl«ig¤ nj‰WÉ¡Fbk‹gij,   
“khj® kfit ts®¥gJngh nyíl«ig   
ahjuth f¤nj‰¿ ah¡ifÆdhš - Ûjhf 
nkÉ al®nehÆ‹ bt¥g¤ij kh‰Wjyh‰ 
nwÉíu bk‹gJlš nj®.” 
v‹D«  nju‹ bghU£ g©ò üÈš Tw¥g£l brŒíshš m¿f.   
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¸ó¾¸õ §ºÕõ ¸¡½¡¸Êì¸¡É ÁÕóÐ¸û 
  
· ¸ó¾¸ §Ä¸¢Âõ:27 
   «Ç×   : 1/4 Ó¾ø 1/2 ÅÃ¡¸¦É¨¼ 
 
   ¾£Õõ §¿¡ö¸û : ¸ÊÅ¢¼í¸û,§ÁçÃø,§Á¸Ý¨Ä 
· ¸ó¾¸ ÌÆ¢¨¾Äõ:29    
       
   «Ç×    : ÅÃ¡¸ý ±¨¼ þÕ §Å¨Ç  
 
   ¸¡Äõ   :   «Ç× 40 ¿¡û 
 
   ¾£Õõ §¿¡ö¸û :  ¸ÕíÌð¼õ,§Á¸çÃø,¸ÕíÌð¼õ 
 
· ¸ó¾¸ ÀüÀõ:27  
   «Ç×   :  2-3 ÌýÈ¢  
 
   ¾£Õõ §¿¡ö¸û :  ¦º¡È¢ º¢ÃíÌ,§Á¸çÃø  
 
· ¸ó¾¸ À¡¸ ÀüÀõ:27  
 
   «Ç×    :  4-5 ÌýÈ¢ 
 
   ¾£Õõ §¿¡ö¸û :  ¦º¡È¢ º¢ÃíÌ, §Á¸Òñ 
 
· ¸ó¾¸ ¦¿ö: 
 
   «Ç×   :   5 Ó¾ø 10 ÐÇ¢ 
  
   ¾£Õõ §¿¡ö¸û :  ¸ÊÅ¢¼í¸û,§ÁçÃø,§Á¸Ý¨Ä, 
¦º¡È¢ º¢ÃíÌ 
  
· ¸Úò¾ ÌÆõÒ:30 
      
   ¾£Õõ §¿¡ö¸û :  ±øÄ¡ Å¢¾ì¸ÊÅ¢¼í¸û,  
       ¸¡½¡¸Ê,ÅñÎ¸Ê 
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· ¸ó¾¸ ±ñ¦½ö:30  
 
   «Ç×   :   488Á¢¸¢(À½¦Å¨¼) 
 
¾£Õõ §¿¡ö¸û :  ¸¢Ãó¾¢ôÒñ,ÅñÎ¸Ê, 
º¢ÃíÌ, ¦º¡È¢, Ìð¼õ, 18Å¨¸ 
Ìð¼õ 
 
  ¸¡Ä«Ç×  :  40 ¿¡û  
 
· ¿£ÃÊ ÓòÐ ÝÃ½õ:29 
 
  «Ç×   ;  11/2 Á¢Ç¸Ç×, ¾¢Éõ þÕ §Å¨Ç  
 
  ¸¡Ä«Ç×  :  40 ¿¡û 
 
   ¾£Õõ §¿¡ö¸û :  âîº¢ ¸Ê¸û,ÌŒ¼õ,  
       §¾Áø,À¼÷¾¡Á¨Ã 
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REVIEW OF THE LITERATURE 
ºí¸ý:  Azima tetracantha Lam 
 
GUNAPADAM ASPECT:8                               
 
§ÅÚ ¦ÀÂ÷¸û: 
 
  ºí¸¦ºÊ 
 
  ¿üºí¸ý 
 
  Óðºí¸ý 
 
ÅÇÕÁ¢¼õ:  
 
  þÐ ¦¾ýÉ¡ðÊý,¸£úì¸¨Ã µÃí¸Ç¢Öõ, þÄí¨¸Â¢Öõ ÀÂ¢Ã¡Ìõ  
 
´ÕÅ¨¸ Óð¦ºÊ,  þ¨Ä ¾ÊòÐõ,þ¨ÄÂ¢ý ÑÉ¢Â¢ø Óû ¯ûÇÐ. 
 
ÀÂýÀÎõ ¯ÚôÒ: 
 
  þ¨Ä :  §Å÷,À¡ø 
 
  Í¨Å :   ¨¸ôÒ  
 
  ¾ý¨Á :   ¦ÅôÀõ 
, 
  À¢Ã¢× :  ¸¡÷ôÒ 
 
¦ºö¨¸:  
 
  º¢Ú¿£÷ô¦ÀÕì¸¢  
 
  ¦ÅôÀÓñ¼¡ì¸¢ 
 
  ÐÅ÷ôÀ¢ 
 
  ¯ÃÁ¡ì¸¢ 
 
  Ó¨È¦ÅôÀ¸üÈ¢ 
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Ì½õ: 
 
þ¾ýþ¨ÄìÌõ§ÅÕìÌõ,§º¡¨À,¸ÃôÀ¡ý,¦ÅôÀõ,ÌýÁõ,¸£øÅ£ì¸õ,Å¡¾§¸¡Àõ, 
ÀÄ ¿îÍì¸û þ¨Å ¿£íÌõ. 
   
‘’Å£ì¸õ ¸ÃôÀ¡ý Å¢¾¡¸õ ¸¢Ãó¾¢ ÌýÁõ 
  
  °ì¸õÁ¢Ì Ý¨ÄÅ¡ö §Å¡ÎÀ¢ò¾-¾¡ìÌÅ¢¼õ 
 
  Å£÷Ú§Á¡ ¸ñÐÄíÌõ Å£ÍÀº¢ Ãò¾Óñ¼¡õ  
 
  ÜÚºí¸õ §ÅÃ¢¨Ä ¸ðÌ’’ 
 
þ¾ý §Å÷ Àð¨¼ìÌ §¸¡¨Æ, þÕÁø, ³ÂÍÃõ, ¸ÎôÒ, ³Â «¨¾ôÒ, ¸¢Ãó¾¢, 
¯ðÍÃõ, ÅÂ¢üÚôÒØì¸û, ¬¸¢Â¨Å ¿£íÌõ. 
 
þ¨Ä ÅÆìÌ:  
 
þ¨ÄÂ¢ý ÌÊ´ù¿£÷ ÅÇ¢ §¿¡ö¸ðÌ ÅÆí¸¢ ÅÃÄ¡õ, þ¨Ä¨Â  «¨ÃòÐ 
«õ¨Á Òñ¸ÙìÌ âº Ì½ÁÌõ. ¸ÃôÀÛìÌõ âºÄ¡õ. 
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ºí¸ý §ºÕõ §¾¡ø §¿¡öì¸¡É  ÁÕóÐ¸û:  
 
· º¢ÃíÌ ¾£Ã ±ñ¦½ö:30  
 
  ¾£Õõ §¿¡ö¸û : ¯¼Ä¢ø âº¢ ¦¸¡ûÇ º¢ÃíÌ ¾£Õõ 
  
· ¸ÃôÀ¡ý ¾£Ã ±ñ¦½ö:30 
 
  ¾£Õõ §¿¡ö¸û : ¿¡û §¾¡Úõ  âº¢ ÀÂýÀÎò¾  
¸ÃôÀ¡ý ¾£Õõ 
   
  À¢È ÁÕóÐ¸û   
 
 
· ºõÀ£Ã ¨¾Äõ: ¾¨Ä ÓØ¸×õ 
 
   
· Ý¨Ä ¾£Ã ±ñ¦½ö: 
 
  ¾£Õõ §¿¡ö¸û :   18 Å¨¸ ¸ÃôÀ¡ý ¾£Õõ  
 
· ¬¼¡§¾¡¨¼ ¦¿ö:  
 
  ¾£Õõ §¿¡ö¸û :   þÕÁø,ÍÅ¡º¸¡ºõ 
 
· þÕÁø ¾£Ã «¨¼ 
  
¾£Õõ §¿¡ö¸û  :   þÕÁø 
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MINARALOGICAL ASPECT 
SULPHUR 
SULPHUR:31  
 Sulphur is a chemical elament, with symbol S it is an abundant, multivalent non 
metal under normal condition, Elimental sulphur is a bright yellow crystalline.  
MORPHOLOGY:  
 Over 50 forms have been noted blochy dipyramidal ones most common. Also 
tubular and sphenoidal, also found.aspowdery coating,massive materials, and in reniform.  
SULPHUR OCCURANCE ; 
 Sulphur occurs mainly in sulfate form as for example calcium sulfate, The most 
important sources of sulphur are the mines sulphur found mainly, in the USA and japan in 
europe the main deposits are in sicily.Natural occurance. Sulphur is widely distributed 
nature. it is found in many minerals and ores. 
Eg  ;   Iiron pyrites cinnabar, zing blende,Epsom salts ,and in minerals it is found 
uncombined in some volcanic regions and in large under ground deposits in sicily 32 
PHYSICAL PROPERTIES ; 
 SYMBOL        : S 
 FORMULA       : S8 
 SYSTEM     ; Arthorhombic 
 ATOMIC NUMBER    : 16 
 COLOUR     : Elimental sulphur is a bright  
yellow crystalline solid 
 MELTING POINT   : 115.2 c 
 HARDNESS   : 1/2 to21/2 
 ATOMIC MASS   : 2.065+ 0.005u 
 DENSITY   : 2.07g/cm3   
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CHEMICAL PROPERTIES:33  
ODUR     : Oderless or faint, rotten  
egg if not100% pure 
 MOLICULAR WEIGHT(g)  : 256.50 
 SOLIBILITY IN WATER  : Inssoluble 
 BOILLING POINT    : 832.f 
 PURITY     : 90% to100%  
ACTIONS:34    
· Antimicrobial activity 
· Antifungal activity  
· Anti bacterial activity  
USES:  
  Sulphur today in the treatment of skin disorders and irritants such as 
eczema,psoriasis, and acne because of antiseptic properties and its essential role in the 
synthesis  of collagen,parasitic infestions ,another common medical use of sulphur both 
today and in the  ancient world, to getriding parasitic infestions such as crab lice,scabies.   
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BOTANICAL  ASPECT 35   
Classification: 
KINGDOM    : Plantae   
 CLADE   : Angiosperms 
CLASS    : Dicatyledons  
SUB CLASS    : Gamopetalae  
SERIES     : Bicarpellatae           
ORDER     : Brassiceles 
FAMILY  : Salvadoraceae 
SPECEIES     : Azima tetracantha (Lam) 
 
LOCAL NAME:14  
Bengali   : Trikantagati 
Hindi    : Katagur  
Sanskrit  : Kundali 
Telugu   : Tella uppi mulsanga 
Kanada   : Billi uppi 
Malayalam   : Changan  
Oriya     : Odibazgo  
Tamil   : Sungam-Chedi  
 
HABITAT : 
 World   : Srilanka, Myanmar, 
 India   : South india near the coast, Orissa,Sundarbans  
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PARTS USED:    
Leaves, root,and juice obtained from root bark, Straggling,armed, busy shrub,up 
to 2m tall, branchlets 4 –gpnous, spines4, axillary.  
LEAVES:  
 Leves elliptic,-obavate. 
FLOWERS:  
 Small , unisexual, greenish white, in axillary fascicles. 
FRUIT:  
 Berry, globose, edible   
ACTION AND USES:  
The leaves are reported to be used for treating ulcers,especially after amall  pox, A 
power ful diuretic given in rheumatism, dropsy, and chronic diarrhea and as astimulant 
tonic after confinement.  
CHEMISTRY:  
 The leaves and stems yield alcoloides-azimin, a small amount of azcarpine and 
minute quantities of carpine.   
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Materials and Methods 
Ash Values 
The Ash values are a measure of the inorganic constituents present in the raw 
drug.  A  high ash content explains its unsuitable nature to be used as a drug  
Total Ash 
A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was  incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from  carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air- dried drug. The procedure was repeated to get the 
constant weight.  
Water soluble ash 
The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot water. The filter paper was dried  
and  ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash.  
Acid insoluble ash 
The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1).  The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed.  
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Elemental Analysis using Atomic Absorption Spectrophotometer 
AAS  of  Gandhaga Maathirai was done in Ramachandra university,chennai 
The elemental analysis of digested samples have been determined by Atomic 
Absorption Spectrophotometer (AAS model 400 Perkin Elmer) at the CARISM, 
SASTRA Deemed University Thanjavur.  The elements like Fe, Cu, Mn, Ni, Zn, Co and 
Pb have been analyzed.  In this method the sample, in the form of a homogeneous liquid, 
is introduced into a flame where thermal and chemical reactions create “free” atoms 
capable of absorbing, emitting or fluorescing at characteristic wavelengths.  Flame 
spectroscopy can be subdivided into the different processes occurring, to give us Flame 
Emission, Atomic Absorption Spectroscopy and Atomic Fluorescence Spectroscopy. 
In Atomic Absorption Spectrophotometer (AAS) the majority of free atoms in the 
commonly used flames were in the ground state, but that the flames did not also have 
enough energy to excite these atoms.  A light source emitting a narrow spectral line of the 
characteristic energy is used to excite the free atoms formed in the flame.  The decrease in 
energy (absorption) is then measured. 
The absorption is proportional to the concentration of free atoms in the flame, given by 
the Lambert-Beer law. 
ABSORBANCE = log 10 I0/It = K.C.L. 
Where, I0 = Intensity of incident radiation emitted by the light source. 
It = Intensity of transmitted radiation 
C = Concentration of sample (free atoms) 
K = Consent (can be determined experimentally) 
L = path length. 
Working standard solutions of Fe, Cu, Mn, Ni, Zn, Co and Pb were prepared from 
stock standard solution of 1000 ppm from MERCK.  Using blank solution to zero the 
instrument performs the Calibration.  The standards are then analyzed and their 
absorbance recorded.  A graph of Absorbance Vs Concentration is plotted.  The 
calibration can be performed in the concentration mode in which case the concentration 
of the sample is read off directly.  Calibration of the instrument was repeated periodically 
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during operation.  A blank reading was also taken and necessary correction was made 
during the calculation of concentration of various elements. In AAS the wave length 
(nm), Flame type, Atomizer, Measurement mode, Lamp source and calibration range 
(ppm) of different elements have been used, are listed in table. 
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BIO -CHEMICAL ANALYSIS OF GANDHAGA MAATHIRAI  
 The biochemical analysis of the Gandhaga Maathirai was carried out in the 
Biochemistry lab, NIS 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample Light green in 
colour 
 
2. Solubility: 
a. A little(500mg) of the sample 
was shaken well with distilled water. 
b. A little(500mg) of the sample 
was shaken well with con. HCl/Con. 
H2So4 
Sparingly soluble 
 
 
Absence of Silicate 
3. Action of Heat: 
   A small amount(500mg) of the 
sample was taken in a dry test tube and 
heated gartly at first and then strong. 
 
No white fumes 
evolved  
 
 
Absence of Carbonate 
 
4. Flame Test: 
  A small amount(500mg) of the sample 
was made into a paste with con. HCl in 
a watch glass and introduced into non-
luminous part of the Bunsen flame. 
No Bluish green 
flame appeared. 
Absence of Copper 
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5. Ash Test: 
   A filter paper was soaked into a 
mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
Yellow colour 
flame appeared. 
Presence of sodium 
 
Preparation of Extract: 
5gm of Gandhaga Maathirai was weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it was boiled well for about 10 
minutes. Then it was cooled and filtered in a 100ml volumetric flask and made up to 
100ml with distilled water. 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1. Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
Cloudy appearance 
present 
 
 
Presence of 
Sulphate 
 
 
 
2. Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
 cloudy 
appearance. 
Presence of 
Chloride 
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ceases. Then 2ml of dil.silver nitrate 
solution was added. 
3. Test For Phosphate: 
 2ml of the extract was treated with 2ml of 
dil.ammonium molybdate solution and 
2ml of con.HNo3. 
No Yellow 
appearance present 
Absence of 
Phosphate 
4 
.  
Test For Carbonate: 
 2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No  Cloudy 
appearance. 
Absence of 
carbonate 
5. Test For Nitrate: 
1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
Absence of 
Nitrate 
6. Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
Absence of 
Sulphide 
7. Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No  Cloudy 
appearance 
 Absence of 
fluoride and 
oxalate 
8. Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
No Characteristic 
changes 
Absence of  
Nitrite 
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9. Test For Borate: 
  2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
   Absence  
of borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
2ml of the extract was added with 2ml of 
dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of Lead 
2. Test For Copper: 
a. One pinch(50mg) of substance 
was made into paste with con. HClin a 
watch glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
Absence of 
copper 
 
 
3. Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
Yellow colour 
appeared. 
 presence of 
aluminium 
4. Test For Iron: 
a. To the 2ml of extract,2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
 
blood red colour 
appeared. 
 
 
 
presence of Iron 
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5. Test For Zinc:  
      To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride was 
added.  
 
White precipitate 
was  formed 
 
presence of Zinc 
6. Test For Calcium:  
      2ml of the extract was added with 2ml 
of 4% dil.ammonium oxalate solution  
Cloudy appearance 
and white 
precipitate was 
obtained 
Presence of 
calcium 
7. Test For Magnesium:  
         To 2ml of extract dil.sodium 
hydroxide solution was added in drops to 
excess. 
 
White precipitate 
was  obtained 
 
Presence of 
Magnesium 
8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
  No Brown colour 
appeared 
 
Absence of 
ammonium 
 
9. Test For Potassium:  
   A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
 
 Yellowish 
precipitate was 
obtained. 
 
presence of 
Potassium 
10. Test For Sodium: 
    2 pinches(50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
 yellow colour 
flame appeared 
Presence of 
sodium 
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11. Test For Mercury:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained 
Absence of 
mercury 
12. Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
 
No brownwish red 
precipitate was 
obtained 
 
Absence of 
arsenic 
 III. Miscellaneous   
1.
  
Test For Starch:  
  2ml of extract was treated with weak 
dil.iodine solution  
 
No  blue colour 
developed 
 
absence of 
starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to boil 
for 2 minutes and added 8 to 10 drops of 
the extract and again boil it for 2 minutes. 
The colour changes are noted. 
 
Brick red colour not 
developed 
 
   Absence of  
reducing sugar 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract was treated with  2ml 
of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  2ml 
of dil.picric acid. 
c)  2ml of the extract was treated with 2ml 
of dil.phosphotungstic acid. 
 
 
Yellow colour 
developed 
 
 
Presence of 
Alkaloid 
4. Test For Tannic Acid:   Black precipitate    abesence  
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    2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
was obtained of Tannic acid 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution was 
added.  
 
Potassium 
permanganate was 
not decolourised 
 
Absence of 
unsaturated 
compound  
6.
  
Test For Amino Acid: 
    2 drops of the extract was placed on a 
filter paper and dried well. 20ml of  
Biurette reagent was added. 
 
No violet colour 
developed 
 
   absence  
of amino acids 
7. Test For Type Of Compound: 
    2ml of the extract was treated with 2 ml 
of dil.ferric chloride solution.  
No green colour 
developed 
 
No red colour 
developed 
 
 
 
No violet colour 
developed 
 
 
No blue colour 
developed 
Absence of oxy 
quinole 
pinephrine and 
pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and 
meconic  
acid are absent  
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
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ACUTE AND SUB ACUTE TOXICITY STUDY ON GANDHAGA MAATHIRAI   
Animals 
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute animal ethics committee and obtained from Vels University, Chennai. They were 
fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. The animals were acclimatized for one week 
under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Gandhaga Maathirai was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The test 
substance was administered in a single dose by gavage using a stomach tube or a suitable 
intubation cannula. The fasted body weight of each animal is determined and the dose is 
calculated according to the body weight.  
 After the substance has been administered, food was withheld for a further 2 hours 
in mice. The animals were observed continuously for the first 4 h and then each hour for 
the next 24 h and at 6 hourly intervals for the following 48 h after administering of the 
test drug, to observe any death or changes in general behaviour and other physiological 
activities. Single animals are dosed in sequence usually at 48 h intervals. However, the 
time interval between dosing is determined by the onset, duration, and severity of toxic 
signs. Treatment of an animal at the next dose was delayed until one is confident of 
survival of the previously dosed animal.  
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Observation of toxicity signs:  
General behavior, respiratory pattern, cardiovascular signs, motor activities, reflexes, 
change in skin and fur, mortality and the body weight changes were monitored daily. The 
time of onset, intensity, and duration of these signs, if any, was recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex (3+3) rats were 
divided into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were administered 
daily with the Gandhaga Maathirai (p.o.) for 28 days at a dose of 1.0, 2.0 and 4.0 g/kg 
respectively. The animals were then observed daily for gross behavioural changes and 
any other signs of subacute toxicity.  
 The weight of each rat was recorded on day 0 and weekly throughout the course 
of the study, food and water consumption per rat was calculated. At the end of the 28 
days they were fasted overnight, each animal was anaesthetized with diethylether, 
following which they were then dissected and blood samples were obtained by cardiac 
puncture into heparinised tubes. The blood sample collected from each rat was 
centrifuged with 3000 X g at 4oC for 10 min to separate the serum and used for the 
biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis glucose, creatinine, total 
protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase 
(ALP)) were automatically determined using autoanalyzer. 
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Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, Liver, Brain, 
Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all rats to 
visually detect gross lesions, and weighed to determine relative organs’ weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparison Test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. 
RESULTS AND DISCUSSION 
 All the animals from control and all the treated dose groups up to 100 mg/kg not 
survived throughout the dosing period of 28 days. Signs of minor or significant 
intoxication were observed in animals from lower to higher dose groups during the dosing 
period of 28 days. Animals from all the treated dose groups exhibited comparable body 
weight gain with that of controls throughout the dosing period of 28 days. Food 
consumption of control and treated animals was found to be comparable throughout the 
dosing period of 28days. Ophthalmoscopic examination, conducted prior to and at the end 
of dosing period on animals from control and all the treated dose groups revealed 
abnormality.  
 Haematological analysis conducted at the end of the dosing period on day 28, 
revealed no significant abnormalities attributable to the treatment. Biochemical analysis 
conducted at the end of the dosing period revealed no remarkable abnormalities 
attributable to the treatment. Functional observation tests conducted at termination 
revealed no abnormalities. Urine analysis, conducted at the end of the dosing period in 
week 4 revealed no abnormality attributable to the treatment. Organ weight data of 
animals sacrificed at the end of the dosing period was found to be comparable with that of 
78 
 
respective controls. Gross pathological examination did not reveal any abnormality. 
Histopathological examination revealed few abnormality. The results of haematological 
investigations conducted revealed no significant changes in the values of different 
parameters investigated when compared with those of respective controls.  
CONCLUSION 
 Over all findings of toxicity profile showed, mild toxic effect was observed 
upto100mg/kg of Gandhaga Maathirai via oral route over a period of 28 days. So, it can 
be concluded that the Gandhaga Maathirai can be prescribed for therapeutic use in human 
with the  dosage recommendations of upto 25mg/kg. body weight p.o 
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HISTOPATHOLOGY SLIDES: 
 
   BONE                                                          INTESTINE 
                                
HEART                                                                     BRAIN     
                                         
 
KIDNEY          LIVER  
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LUNG                                  OVARY 
                  
 
PANCREAS       SPLEEN                     
                  
                                  
  STOMACH       TESTIS 
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EVALUATION OF ANTIHISTAMINIC ACTIVITY OF GANDHAGA 
MAATHIRAI 
INTRODUCTION 
 Histamine plays an important role in the symptomatology of allergic reactions. 
Drugs which have the capacity to control the histamine release and its further effects can 
be called as antihistaminic or antiallergic drugs. Siddha is a traditional Indian Medicinal 
System practiced for thousands of years. traditional medicines are being used by nearly 
about 60-80% of the world population, primarily in developing countries for primary 
health care. Selection of scientific and systematic approach for the systematic biological 
evaluation of Siddha formulations based on their use in the traditional systems of 
medicine forms the basis for an ideal approach in the development of new drugs.  
  
Siddha medicines are being increasingly utilized to treat a wide variety of 
diseases, though the knowledge about their mode of action is relatively scanty. Allergies 
occur when a hypersensitive immune system reacts to a common or unusual substance. 
The number of individuals suffering with allergic illnesses is increasing in the 
industrialized, as well as in large cities of developing countries. Allergies also have 
reached high prevalence and incidence in all over the world. Most of the allergic diseases 
are due to allergens like airborne pollens (grass, trees, and weeds), house-dust, mites, 
animal dander, cockroaches, fungal spores, etc. Overproduction of histamine in body 
triggers the allergic and inflammatory responses. Hence to identify a better antihistaminic 
drug, the present study was undertaken to scientifically evaluate and prove the traditional 
claim of the antihistaminic potency of Gandhaga mathirai.  
The experimental protocol used in this study was approved by IAEC. 
(XIII/VELS/PCOL/31/2000/CPCSEA/IAEC/08.08.2012). 
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MATERIALS AND METHODS 
Drugs and Stock Solution  
 Drugs used were Histamine Hcl (Sigma Chemical, USA) Histamine hydrochloride 
was dissolved in distilled water and desired concentrations were prepared. The test drug 
Gandhaga Mathirai concentration was 100microgram per ml prepared by suspending with 
2% CMC and then the volume was adjusted to 10 ml with normal saline for making the 
concentration of 100μg/ml in distilled water. 
Animals and In-vitro antihistaminic study 
 Guinea pig was sacrificed and a segment from ileum (2cm) was dissected from the 
terminal ileum and mounted in an organ bath containing Tyrode solution (10ml) between 
two stainless steel hooks under 0.5 to 1 g initial tension. The lower hook was fixed at the 
bottom of the organ bath and upper one was connected to an isotonic transducer. The 
Tyrode solution composition (pH 7.4) was (concentration in gm/lit.) NaCl 8.0, KCl 0.2, 
CaCl2 0.2, MgCl2 0.1, NaHCO3 1.0, NaH2PO4 0.05, and Glucose1.0gm/liter.  It was 
continuously aerated and maintained at 37 ± 0.5ºC The equilibrium period was 60 min 
and the bath solution was refreshed every 15min. After equilibrium period, a dose 
response curve for histamine in variant molar concentrations, by maintaining 45min time 
cycle.  
Statistical Analysis 
 Ileum contractions induced by agonist were assumed as 100% and reductions 
induced by test drug calculated. Percentage of ileum contraction was expressed as mean ± 
SEM. Results were analyzed using one-way analysis of variance (ANOVA). Probability 
value less than 0.05 were considered as significant  
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RESULTS AND DISCUSSION 
 In isolated guinea pig ileum preparation, a right side shift of dose response curve 
of histamine was observed in the presence of the Gandhga Maathirai indicating 
antihistaminic action. It was observed that antihistaminic activity in Gandhga Maathirai 
was effective. The resultant antihistaminic effect may be caused by the suppression of 
antibody production and stabilization of the mast cell membrane, inhibition of antigen-
induced histamine release or non-availability of antibodies on the mast cell surface.  
  
CONCLUSION 
 Histamine produces dose dependent contraction of Guinea pig ileum preparation. 
In the present study, Thus, it can be concluded from the results obtained the Gandhga 
Maathirai significantly inhibited (p<0.01) the histamine-induced contraction of isolated 
Guinea pig tracheal chain preparation and found to be effective can be used as a 
antihistaminic agent clinically for mild to moderate allergic symptoms.  
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DISEASE ASPECT 
SIDDHA ASPECT 
¸¡½¡ì¸Ê36 
 ¨¸,¸¡ø ¯¼õÀ¢ý §ÅÚ ÀÌ¾¢¸Ç¢ø ¾¢É× ±ÎòÐ ¦º¡È¢ó¾¡ø «íÌ 
¾¢ðÎò¾¢ð¼¡¸ ¾ÊôÒñ¼¡¾ø,¾¢É× Á¢¸ «¾¢¸Ã¢ò¾ø ¬¸¢Â ÌÈ¢Ì½í¸û 
¸¡½ôÀÎõ.þÐ ´ùÅ¡¨Á «øÄÐ §¿¡öò¾ÊôÒ¸û ±ýôÀÎõ. ´ùÅ¡¾ 
¾ý¨ÁÔûÇ ¦À¡Õð¸¨Ç ¯ñÏ¾ø, ´ùÅ¡¾ ¾ý¨ÁÔûÇ ¦ºÂø¸¨Ç ¦ºö¾ø 
ÁÕóÐ¸Ç¢É¡ø ´ùÅ¡¨Á ¬¸¢ÂÅüÈ¡ø ¯ñ¼¡¸¢ÈÐ. §ÁÖõ º¢Ä ¾ÊôÒ¸û 
¯¼Ä¢ý ¾£Â ²ÁîºòÐ¸Ç¢É¡ø ¯ñ¼¡¸¢ÈÐ. 
ÌÈ¢Ì½í¸û: 
 «Ã¢ôÒ, ¾ÊôÒ ¯¼õÀ¢ý §¾¡ø Á£Ð Àð¨¼ Àð¨¼Â¡¸ º¢Åó¾ ¿¢Èò¾¢ø 
ÅÎì¸û ¯ñ¼¡¾ø. þÃÅ¢ø ¾ÊôÒ¸û ¯ñ¼¡¾ø.áy tif jo¥òfŸ V‰gLtj‹ 
fhuz« rÇahf¤ bjÇaÉšiy. vdnt ïij x›thik vdî« brhšt®.  
fhzh¡fo v‹W« brhšy¥gL«. kUªJfŸ x›thikahY« njhÈš jo¥òfŸ 
V‰glyh« ïj‰Fm«kUªJfis ÃW¤âÉ£L mitfS¡F KÇî bröa¤  
jo¥òfŸ khW«  ïªnehÆš ky¤ij¡ fÊ¤J, áWÚiu¥ bgU¡F«  kUªJfS«, 
tH§fyh«. 
ÓìÌüÈ Á¡ÚÀ¡Î: 
 "Å¡¾ÁÄ¡Ð §ÁÉ¢ ¦¸¼¡Ð" 
    -§¾Ãý. 
Å¡¾ ¿¡ÊÂ¢ý À¡¾¢ôÀ¢É¡ø þó§¿¡ö ¯ñ¼¡¸¢ÈÐ.  
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MODERN ASPECT 
DEFINITION:39  
                       Urticaria is characterized by transient, superficial cutaneous 
swellings(wheals or Hives) caused by transudation of plasma from the dermal 
capillaries,It is not a singal disease but a  reaction pattern that represents cutaneous mast 
cell de granulation.  
Prevalence:37 
                     Approximately 15 to 20% of the general population will have urticaria at 
least once During their life time. 
                   World allergy organization (WAO) urticaria is a frequent disease.the life  
time  Prevalence for any sub type of urticaria is approximately 20%.38 
Causes of urticaria:39 
Foods, Nuts ,Legumes,   Milk , Soy, wheat 
Food allergies: (shell fish, eggs, mushrooms, prawn) 
Emotional stress      
Aero allergen 
Dust mites 
Pollens 
Animal dander 
Infection:               
Viral,  Parasitic,  Fungal or bacterial  
 PHYSICAL STIMULI:  
Exposure to sun, Water or temperature externs  
  CLINICAL FEATURES:   
Urticaria is due to localized capillary vaso dilation, followed by  Extravasation of 
protein rich fluid in to the surrounding tissue ,  It is characterized by the  Appearance of a 
tr transient migratory pruritic, rash with raised,round or oval patches that  Blanch on 
86 
 
pressure,  wheals, Lesion often have a pale centre and are surrounded by an area of  
Erythema.  
AGE:   
               Acute urticaria is more common in children and young adults, Chronic urticaria 
is More common in adults.  
GENDER:    
Over all the male,female ratio for chronic urticaria is 1;2,women singinificantly  
Out number men in dermographism and cold urticaria.     
CLASSIFICATION:   
· ACUTE URTICARIA: 
Acute urticaria is usually defined as urticaria lasting less than 6 weeks, 
· CHRONIC URTICARIA:   
Chronic urticaria is usually as urticaria, lasting more than 6 weeks  
· PHYSICAL URTICARIA:  
Physical urticarias are characterized by the predominant physical stimulus 
that elicits them,they may overlap.  
· COLD URTICARIA:   
  More common in children and young adults, wheals occur in areas  
· SOLAR URTICARIA: 
Exposure to the sun results in the rapid on set of urticaria usually  
· AQUAGENICURTICARIA:                                 
This occurs in contact with water  
· DERMATOGRAPHIA: 
This is the most commom physical,  urticaria.it may be elicited by  firmly 
stroking the skin.           
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· CHOLENERGIC URTICARIA:  
Wheals (tipically,small,popular) occur when the individual becomes hot. 
· NONIMMUNOLOGICAL (CONTACT) URTICARIA:  
Animals, Plants, Therapeutic agents 
AETILOGICAL FACTORS:  
Infection,  certain infection have been implicated in the etiology of  
urticaria,including dental and sinus  infection,HBV,helicobacter  pylori infection,and 
herpes simplex virus and parasitic infection  
· AUTOIMMUNE DISEASES:   
Urticaria has been associated with a number of autoimmune diseases, including 
SLE,juvenile rheumatoid arthritis  
· MALIGNANT DISEASES:  
Urticaria has been associated with malignant condition   
· CHRONIC IDIOPATHIC URTICARIA (CIU):   
No cause is established  for their urticaria are said to have CIU.  
· INVESTIGATION:  
Complete blood count with differential count 
Erythrocyte sedimentation rate  
Stool analysis for ova and parasites  
Specific IgE test     
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CLINICAL STUDY 
The study was conducted on patients with Kaanakadi (Urticaria) patients 
satisfying the inclusion criteria.  
The study  was conducted at the OPD/IPD of Ayothidoss Pandithar Hospital of 
the National Institute of Siddha, Tambaram sanatorium, Chennai-47. 
Sample size:  
The trial size was 20 patients. 
Inclusion criteria: 
 Age  : 20-60 years 
 Sex  :  both sex male and female 
 Symptoms:   
   Itching 
   Whealing 
   Rashes 
   Scratch marks  
Erythema 
The patients with any four of the above symptoms with increased IgE level willing to 
attend the OPD on every 7th day were admitted to the trial. 
Exclusion criteria: 
   Diabetes mellitus 
   Uraemia 
   Biliary diseases  
   Oozing and ulceration  
Any other serious illness  
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Withdrawal criteria:  
   Development of any adverse reaction 
   Occurance of any other serious illness 
   Non-co operation of the patient  
TRIAL DRUG AND DURATION 
 Drug  :  Gandhaga Maathirai -130mgbd with  palm gaggery,  
     after food.                                                              
Duration of the treatment : 40 days. 
Conduct of the study: 
Kaanakadi patients satisfying inclusion and exclusion criteria were admitted to the 
trial. Informed consent was obtained from the patients. Routine investigations like Blood 
test, urine test, and IgE were carried out before and after the trial treatment. For in 
patients the drug was administered daily. For out patients the trial drug was issued for 
seven days course.  
They were advised to visit the OPD once in 7 days. At each visit they were 
clinically assessed. 
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Clinical observation: 
For the clinical study of “Gandhaga Maathirai’’ on Kaanakadi”. 20 patients were 
selected.   
Among 20 patients,   12 ( 60%) were in female, 8 ( 40%) were in male.  
According to age wise distribution 10% were in 20-30 years,45 % were in 31-40 
years and  45% were in 41-60 years. 
Among 20 patients, All patients were affected from Itching , 19 patients were 
affected from whealing,   16 patients were affected from Rashes,  15 patients were 
affected from scratch marks, and 6 patients were suffering from Erythema. 
From the clinical study 85% of patients relieved from Iitching, 78.95% of patients 
relieved from wheals, 75% of patients relieved from Rashes, 73.33% of patients relieved 
Scratch marks, 62.5% of patients relieved from Erythema and no adverse effects were 
observed During trial period.  
 16 (80% ) patients had  a significant reduction in the IgE levels after the treatment.  
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DISCUSSION 
 The drug Gandhaga Maathirai was selected to find out the H1-histamine 
antagonistic activity in The Management of Kaanakadi (Urticaria). 
 The literary evidence from the text Anuboha Vaithiya Navaneetham part 6 
strongly supports the H1-histamine antagonistic activity of the drug. 
Biochemical analysis: 
The Biochemical analysis of the drug reveals the presence of sulphate sodium, 
chloride, alluminium, iron, zinc, calcium, magnesium, potassium and alkaloids. 
Sulphur:40 
 Phosphoadenosine phosphosulphate (PAPS) is the active sulphate utilized for 
several reactions, Especially in the detoxification mechanism.It is needed for the 
detoxification mechanism ie production of indoxyl sulphate. 
Zinc:41 
Iit helps repaire damaged tissues and heals wounds,  zinc may help nip zits in the 
buds by reduceing the amount of natural oil,or sebum,produced in the skin .  
Magnesium, calcium:43  
Magnesium can be used as an substitution treatment in Urticaria.calcium also 
regulates normal skin colour by stimulating melonocytes,the cells that produce pigment. 
Iron:42 
 It is required for the formation of. Haemoglobin and myoglobin are required for 
the transport of oxygen and carbondioxide. It is associated with the immuno competence 
of the body. 
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Toxicological studies: 
Acute oral toxicity study: 
Based on these findings, no toxic effect was observed up to 1000mg/kg of  
Gandhaga Maathirai treated via oral route over a period of 28 days, at the dose of 
1000mg/kg/po did not exhibit any mortality in rats. As per OECD 425 guidelines.  
  Pharmacological studies: 
In the pharmacological studies the drug Gandhaga maathirai exhibits significant 
anti-histaminic activity against low and higher doses of histamine. 
Clinical observation:  
From the clinical study 85% of patients relieved from itching, 78.95of patients 
relieved from wheals, 75% of patients relieved from Rashes, 73.33% of patients relieved 
from scratch marks 62.5% of patients relieved from erythema and no adverse effects were 
observed during trial period. 
16 (80%) patients had a significant reduction in the IgE levels after the treatment. 
Bio-statistics: 
              Statistically, the paired ‘t’ test shows statistical significance for the symptoms 
before and after the treatment. (p<0.0001).  
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SIDDHA ASPECT 
 þõÁÕó¾¢ø, ¸ó¾¸õ   ÁüÚõ  ºí¸ý þ¨Äîº¡Ú §ºÕ¸¢ýÈÐ.  
¸ó¾¸õ:   
Í¨Å -¨¸ôÒ, 
  ÐÅ÷ôÒ   
ºí¸ý :  Í¨Å  -¨¸ôÒ,  
 ¨¸ôÒ Í¨ÅÂ¢ý ¾ý¨Á: ¨¸ôÒ ¿îÍì¸¨Ç ¿£ìÌÅ¾¢ø º¢ÈôÒ¨¼ÂÐ 
        "Ì¼üÒØ Ìð¼õ ¦¸¡ÊÂ ¿ïÍ   
    Å¡ö¿£ÕÈø «Æüº¢Ôõ ¾½¢ìÌõ." 
±ýÀ¾¡ø þÐ §¾¡ø §¿¡ö¸¨Çô §À¡ìÌõ ¾ý¨ÁÔûÇÐ. ÐÅ÷ôÒ Í¨Å 
ÌÕ¾¢¨Â àö¨Á ¦ºöÔõ±ýÀ¾¡ø, þ¨¾ §¾¡ø §¿¡Â¡¸¢Â ¸¡½¡¸ÊìÌ 
ÅÆí¸Ä¡õ.  
Hence, Ganthaga Maathirai is a better drug of choice in  the management of Kaanakadi. 
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SUMMARY 
The literary evidence strongly support the H1-histamine antagonistic activity of    
Gandhaga Maathirai. 
The drug Gandhaga Maathirai has been selected for this study to evaluate its  
efficacy on the H1-histamine antagonistic activity in the management of Kaanakadi 
(Urticaria).Biochemical analysis of the drug gandhaga maathirai reveals the presence of 
sulphate sodium ,chloride, alluminium, iron, zinc, calcium and magnesium, 
pottasium, alkaloides,  
In the toxicological studies, the drug does not exhibit any mortality upto the dose 
of 1000mg/kg/po. 
In the pharmacological studies the drug Gandhaga Maathirai exihibits significant 
anti-histaminic activity against low and higher doses of histamine. 
From the clinical study 85% of patients relieved from itching, 78.95% of patients 
relieved from wheals, 75% of patients relieved from rashes, 73.33% of patients relieved 
from scratch marks, 62.5% of patients relieved from Erythema and no adverse effects 
were observed during Trial period.  
16 (80%) patients had a significant reduction in the IgE levels after the treatment. 
 From the statistical analysis-paired‘t’ test, the drug Gandhaga Maathirai is 
statistically Significant. 
Statistically, the paired ‘t’ test shows statistical significance for  symptoms before 
and After the treatment.(p<0.0001) 
The drug GandhagaMaathirai has 
§ Anti-histamine (H1-receptor antagonism) Activity. 
§ No side effects 
§ No undoing effects 
§ Encouraging clinical results.  
From the clinical and statistical analysis it is proved that the drug Gandhaga 
Maathirai is   Satistically Significant on H1 histamine antagonist activity in the 
management of Urticaria. 
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CONCLUSION 
From the literary evidences, phytochemical review and bio chemical, 
toxicological and pharmacological studies, it is concluded that drug Gandhaga Maathiri 
has significant H1-Histamine Antagonistic activity. Thus it gives a new hope in the 
management of Kaanakadi (Urticaria). 
 
 
TABLES FOR TRAIL DRUG-1 PAVATTAIVER  KUDINEER CHOORNAM 
QUALITATIVE ANALYSIS: 
.S.NO PARAMETERS RESULTS 
1. Phosphate  present 
2. Sulphate abesent 
3. Redusing sugar present 
4. Iron Present 
5 Aluminium Present 
6. Starch present 
7. ammonia Present 
8. sodium Present 
9. alkaloids Present 
10. Reducing sugars present 
 
 
                                          PHYSICAL PROPERTIES 
 
 
 
 
 
 
 
 
S.No Characteristic test Results 
1. pH 4.6 
2. Ash value  0.97 
3. Water soluble ash 0.01 
  
Fingerprint chromatogram of RH -1 at 404nm 
107  Finger Printing  
254nm 
 
254nm at 3D Display (No: 107 -01) 
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298 nm at 3D Display   (No: 107 -07) 
 Derivatisation 5 l at 298nm (No: 107 -08) 
 
 
 
Derivatisation 10 l at 298nm (No: 107 -09) 
 
 
 Derivatisation (489nm) 
 
    489 nm at 3D Display (No: 107 -10)    
 
 
Derivatisation 5 l at 489nm (No: 107 -11) 
 
 Derivatisation 10 l at 489nm (No: 107 -12) 
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Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
N
o 
Dose 
mg/k
g 
1 2 3 4 5 6 7 8 9 
1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
1. 1000 + - - + - + - - - - - - - - - - - - - - 
2 2000 + - - + - + - - - - - - - - - - - - - - 
3 5000 + - - + - + - - - - - - - - - - - - -  - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. 
Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. 
Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
 
Table 2. Body wt (g) of rats exposed to Pavattai ver kudineer chooranam for 28days. 
Dose 
(mg/kg/day) 
Days 
1 7 14 21 28 
Control 154.12 1.00 155.25 1.45 157.02 2.8 161.18 2.4 164.26 2.8 
100 151.14 2.88 152.4 1.33 152.44 2.24 154.20 2.1 156.2 3.2 
250 154.12 2.60 153.17 1.01 155.15 1.24 156.22 2.00 158.14 2.8 
500 150.10 5.21 156.45 5.00 156.75 4.22 158.18 7.2 161.32 4.00 
 
Values are mean  S.E.M. (Dunnet t' test). nsP>0.05; Vs Control N=6. 
  
Table 3. Food (g/day) intake of rats exposed to Pavattai ver kudineer chooranam for 
8days. 
Dose 
(mg/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 44.15 2.65 40.18 2.16 44.21 2.62 45.00 2.18 44.12 2.10 
100 42.33 2.44 45.10 2.12 48.54 2.71 45.12 2.45 45.15 2.47 
250 44.25 2.41 45.00 2.14 45.69 2.25 44.88 2.28 46.20 2.15 
500 46.10 2.29 48.45 2.20* 48.64 2.74 49.40 2.46 47.54 2.41 
Values are mean  S.E.M. (Dunnet t' test). *P<0.05 Vs Control N=6. 
Table 4. Water (ml/day) intake of rats exposed to Pavattai ver kudineer chooranam 
for 28days. 
 
Dose 
(mg/kg/day) 
Days (ml/rat) 
1 7 14 21 28 
Control 47.43 2.44 42.92 2.45 42.20 2.88 45.28 3.43 42.88 2.48 
100 44.12 2.28 43.24 3.00 43.44 3.32 44.12 3.02 45.00 2.12 
250 42.50 2.64 42.64 2.64 43.10 3.26 42.28 2.42 44.18 2.55 
500 44.28 2.28 44.44 2.28 45.45 3.04 45.40 3.40 45.45 3.20 
Values are mean  S.E.M. (Dunnet t' test). nsP>0.05 Vs Control N=6. 
Table 5. Hematological parameters after 28days treatment with Pavattai ver 
kudineer chooranam 
Parameter Control 100 mg/kg 250 mg/kg 500 mg/kg 
Red blood cell (mm3) 4.28 0.40 4.88 0.35 4.62 0.38 4.20 0.21 
HB (%) 14.41 0.5 14.0 0.72 14.46 0.42 14.22 0.29 
Leukocyte(x103/Cu.mm) 3.12 0.3 3.12 0.42 3.31 0.40 2.54 0.32 
Platelets(K/ l) 1.15 0.10 1.44 0.21 1.48 0.24 1.42 0.28 
MCV (gl) 85.48 4.0 85.18 4.1 85.44 3.88 85.10 4.22 
Neutrophil 45.10 4.44 45.14 3.1 46.10 2.9 47.14 3.82 
Lymphocyte 42.00 0.6 42.18 0.8 44.20 1.0 45.12 2.44 
Monocyte 4.8 0.02 4.2 0.2 4.8 0.3 3.8 0.3* 
Eosinophil 6.4 0.37 6.32 0.4 5.5 0.4 5.6 0.4 
Basophil 0 0.00 0 0.00 0 0.00 0 0.00 
ESR(mm) 1 00 1 00 1 00 1 00 
PCV 46.02 2.1 45.12 2.44 44.14 2.64 44.19 2.78 
Values are mean  S.E.M. (Dunnet t' test). *P<0.05; Vs Control N=6. 
 
 
 
 
 
 
Table 6. Effect of treatment with Pavattai ver kudineer chooranam biochemical 
parameters. 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Total Bilirubin 
(mg/dL) 
0.24 0.02 0.23 0.02 0.24 0.02 0.30 0.08 
Bilirubin direct 
(mg/dL) 
0.02 0.00 0.02 0.01 0.00 0.00 0.03 0.10 
ALP (U/L) 50.00 4.12 48.74 3.79 52.15 3.00 50.11 4.00 
SGOT (U/L) 128.1 5.46 131.02 5.11 132.45 5.18 142.16 6.12 
SGPT(U/L) 26.22 1.54 25.77 2.00 26.02 1.76 27.10 1.99 
Total Protein(g/dl) 5.10 0.22 5.17 0.17 5.51 0.12 5.14 0.15 
Albumin(g/dl) 3.88 0.04 3.74 0.05 3.14 0.08** 3.20 0.07** 
Globulin(g/dl) 3.90 0.12 4.00 0.20 4.36 0.22 4.19 0.20 
Values are mean  S.E.M. **P<0.01. Vs Control N=6. 
 
 
 
 
 
 
Table-7 RFT 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Urea ( g/dL) 32.10 4.1 34.44 4.0 33.61 4.2 33.64 4.12 
Creatinine (mg/dL) 30.45 2.4 28.19 3.1 28.71 3.4 29.88  5.44 
Uric acid (mg/dL) 3.42 0.06 3.11 0.09* 3.15 0.06 1.31 0.09** 
Na m.mol 147.18 0.77 152.04 1.02** 156.02 1.05** 151.89 0.50** 
K m.mol 5.89 0.60 6.12 1.04 6.11 0.05 5.99 0.09 
Cl m.mol 102.56 3.51 101.71 4.26 102.10 4.42 102.45 5.10 
Values are mean  S.E.M. **P<0.01. Vs Control N=6. 
Table-8. Lipid Profile 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Total cholesterol (mg/dL) 55.00 5.10 56.10 5.62 55.07 5.42 54.46 3.11 
HDL(mg/dL) 99.82 0.28 102.1 0.24 106.05 0.25** 108.11 0.56** 
LDL(mg/dL) 61.14 2.70 58.40 4.66 64.62 0.58 67.42 3.23 
VLDL(mg/dl) 25.14 2.20 24.72 2.12 25.00 2.19 25.61 2.41 
Triglycerides (mg/dl) 26.81 4.8 26.95 5.01 27.18 4.22 28.64 4.82 
Blood glucose(mg/dl) 100 12.1 98.34 10.2 102.2 12.4 104.2 10.12 
Values are mean  S.E.M. **P<0.01. Vs Control N=6. 
 
Table-9 Urine Analysis 
Parameters Control 100 mg/kg 250 mg/kg 500 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly 
cloudy 
Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >7.5 >7.5 
Protein Nil 1+ 1+ 2+ 
Glucose Nil Nil Nil Trace 
Bilirubin -ve -ve -ve -ve 
Ketones -ve -ve -ve -ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Normal Normal Normal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
 
 
 
 
 
 
 
 
 
Table 10. Effect of Pavattai ver kudineer chooranam on organ weight 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Liver (g) 6.22 0.36 6.47 0.32 6.52 0.30 6.32 0.30 
Heart (g) 1.25 0.04 1.28 0.05 1.10 0.04 1.22 0.04 
Lung (g) 1.80 0.11 1.74 0.05 1.76 0.04 1.72 0.05 
Spleen (g) 0.89 0.04 0.84 0.04 0.84 0.04 0.88 0.04 
Ovary (g) 0.08 0.00 0.08 0.02 0.09 0.04 0.06 0.02 
Testes (g) 2.14 0.12 2.10 0.12 2.14 0.14 2.00 0.12 
Brain (g) 1.88 0.04 1.79 0.03 1.82 0.05 1.90 0.05 
Kidney (g) 1.24 0.05 1.20 0.03 1.18 0.04 1.21 0.04 
Stomach (g) 1.15 0.14 1.12 0.10 1.15 0.12 1.17 0.18 
Values are mean  S.E.M. (Dunnet t' test). nsP>0.05; Vs Control N=6. 
 
 
 
 
  
Table: 1 Effect of Pavattaiver Kudineer Chooranam on ethanol induced 
hepatotoxicity 
 
Values are mean  S.E.M. (Dunnet t' test). **P<0.015 Vs Control N=6. 
 
 
 
S.No. Groups Total 
Bilirubin 
(mg/dl) 
SALP 
(Units/ml) 
SGPT 
(Units/ml) 
SGOT 
(Units/ml) 
1. Control 
(2%CMC) 1 ml 
0.92  0.14** 234.95 12.10** 74.16  
1.20** 
187.15  
12.42** 
2. 50% Ethanol 
12ml / Kg 
2.42  0.37 431.40 13.20 365.45 2.18 324.10  
19.21 
3. PVKC 
(250mg/kg) 
0.126  0.15** 269.54 17.43** 94.22  
3.41** 
236.28  
10.55** 
4. PVKC 
(250mg/kg) 
0.107  0.18** 248.42 14.10** 86.14  
3.02** 
212.00  
15.12** 
5. Silymarin 
(200mg/kg) 
0.84  0.08** 239.33 10.25** 79.10  
22.35** 
198.94 
16.47** 
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GENDER DISTRIBUTION:   
KALLEERAL NOI 
S.NO GENDER NO.OF 
PATIENTS 
PERCENTAGE 
1. MALE 20 100% 
 
AGE  DISTRIBUTION:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO. AGE NO.OF PATIENTS 
1. 20-30 4 (20%) 
2. 31-40 6 (30%) 
3. 41-60 10(50%) 
20%
30%
50%
1
2
3
IMPROVEMENT  SHOWING SIGNS AND SYMPTOMS BEFORE AND AFTER TREATMENT  
KALLEERAL NOI PATIENTS. 
 
 S.NO Symptoms Before Treatment               After Treatment 
 
No 
improvemernt 
Improvement 
1 anorexia 20(100%) 3 (15%) 17(85%) 
2 malaise 17 (85%) 4(23.52 %) 13 (76.48 %) 
3 nausea 16(80%) 5 (31.25%) 11(68.5%) 
6 vomiting 15 (75%) 3 (20%) 12(80%) 
5 Upper abdomenal 
pain 
16(80%) 4(25%) 12(75%) 
6 jaundice 7(35%) 3(42.85%) 4(57.15%) 
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ANOREXIA MALAISE NAUSEA VOMITING U AB PAIN JAUNDICE
  KA LEERAL NOI ( ALCOHOLIC LIVER DISEASE) 
Paired t test for Symptoms before and after treatment: 
Variable patient Mean Std.dev t.value P value 
Before 
symptoms 
20 
 
4.60  0.88 
 
14.44 P<0.0001 
After 
symptoms 
20 1.05 0.94 
 
For Symptoms the mean and_standard deveation before treatment is 4.60 0.88 and after 
treatment is 1.05 0.94 which is statistically significant(p<0.0001). 
 
 
Paired t test for T BILIRUBIN before and after treatment: 
Variable patient Mean Std.dev t.value P value 
Before 
treatment 
20 
 
1.00 0.52 4.17 P<0.0001 
After 
treatment 
20 0.68 0.37 
 
For T BILIRUBIN, the mean  and standard deveation efore treatment 1.00 0.52 and after 
treatment is 0.68 0.37 which is statistically significant(p<0.0001). 
  
 Paired t test for SGOT before and after treatment: 
Variable patient Mean Std.dev t.value P value 
Before 
treatment  
20 
 
75.00 32.93 8.45 P<0.0001 
After 
treatment 
20 37.95 17.52 
 
For SGOT, the mean and standard deveation  before treatment is 75.00 32.93and after 
treatment is 37.95 17.52 which is statistically significant(p<0.0001). 
 
 
Paired t test for SGPT before and after treatment: 
Variable patient Mean Std.dev t.value P value 
Before 
treatment 
20 
 
58.90 15.78 10.38 P<0.0001 
After 
treatment 
20 29.90 12.76 
 
For SGPT,  the mean and standard deveation  before treatment is 58.90 15.78 and after 
treatment is which is  29.90 12.6 statistically significant(p<0.0001) 
 
 
 
 
 
 
TABLES FOR TRAIL DRUG-2 GANDHAGA MAATHIRAI  
 QUALITATIVE ANALYSIS: 
.S.NO PARAMETERS RESULTS 
1. chloride present 
2. Sulphate Present 
3. Magnesium Present 
4. Iron Present 
5 Alluminium Present 
6. Zinc present 
7. Sodium Present 
8. Alkaloides Present 
9. Calcium Present 
10. Pottasium present 
 
 
PHYSICAL PROPERTIES 
 
S.No Characteristic test Results 
1. pH 4.6 
2. Ash value  0.96 
3. Water soluble ash 0.02 
  Qualitative Analysis 
 
  
S.No. Phrameters  Results 
1. Calcium Trace 
2. Iron (Ferric) - 
3. Iron (Ferrous) + 
4. Chloride + 
6. Potassium + 
7. Sodium + 
8. Sulphate + 
 Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
N
o 
Dose 
mg/k
g 
1 2 3 4 5 6 7 8 9 
1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
1 500 + - - + - + - - - - - - - - - - - - - - 
2 1000 + - - + - + + + - - + - - + - - - - + - 
3 2000 + + - + - + + + + - + - + + - - + + + + 
4 5000 + + - + 
 
+ + + + - + - + + - - + + + + 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. 
Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. 
Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
  
 
  
Table 2. Body wt (g) of albino rats exposed to Gandhaga Mathirai for 28days. 
Dose 
(mg/kg/day) 
Days 
1 7 14 21 28 
Control 150.4 2.40 152.10 2.18 156.17 2.4 158.15 2.16 158.88 3.32 
25 150.5 2.25 153.21 2.66 154.12 0.21 156.42 0.24 157.2 6.10 
50 154.4 3.55 155.30 2.08 155.44 2.25 158.20 3.12 162.11 2.52 
100 148.2 4.21 151.11 3.10 153.48 2.17 157.00 5.10 159.00 4.12 
Values are mean  S.E.M. (Dunnet t' test). nsP>0.05. N=6. 
Table 3. Food (g/day) intake of rats exposed to Gandhaga Mathirai for 28days. 
Dose 
(mg/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 41.11 2.34 42.10 2.11 45.17 2.18 45.12 2.18 44.26 2.18 
25 40.41 2.42 42.14 2.18 44.48 2.28 45.04 2.52 45.18 2.44 
50 40.20 2.22 42.52 2.12 43.14 2.40 44.20 2.40 43.61 2.10 
100 41.12 2.21 41.24 2.45 43.20 2.55 44.55 2.52 45.10 2.26 
Values are mean  S.E.M. (Dunnet t' test). nsP>0.05 Vs Control N=6.  
 
 
Table 4. Water (ml/day) intake of rats exposed to Gandhaga Mathirai for 28days. 
 
Dose 
(mg/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 45.30 2.22 42.42 2.78 44.12 4.10 45.25 3.00 42.23 3.02 
25 40.42 2.20 43.41 3.00 45.10 2.88 44.12 3.11 45.42 2.10 
50 44.36 2.24 42.18 2.41 43.56 2.56 42.28 2.26 47.14 3.15 
100 42.41 2.35 44.62 2.18 45.24 2.44 45.20 3.40 45.24 3.25 
Values are mean  S.E.M. (Dunnet t' test). nsP>0.05 Vs Control N=6. 
 
 
Table 5. Hematological parameters after 28days treatment with Gandhaga Mathirai. 
Parameter Control 25mg/kg 50mg/kg 100mg/kg 
Red blood cell 
(mm3) 
4.48 0.35 4.40 0.30 4.42 0.30 4.21 0.22 
HB (%) 14.12 0.42 14.4 0.40 14.24 0.22 14.18 0.24 
Leukocyte 
(x103/Cu.mm) 
3.12 0.3 3.10 0.4 3.62 0.31 3.70 0.32 
Platelets(K/ l) 1.34 0.22 1.42 0.24 1.40 0.22 1.50 0.20 
MCV (gl) 85.10 4.20 86.18 4.12 85.14 3.88 85.56 4.00 
N 47.10 4.52 46.14 2.4 47.12 2.5 47.12 3.0 
L 27.12 0.4 26.12 3.10 28.24 2.40 25.10 2.12 
M 2.0 0.02 2.2 0.2 2.1 0.3 2.4 0.2 
E 3.2 0.40 5 0.5* 4 0.4 4 0.4 
B 0 0.00 0 0.00 0 0.00 0 0.00 
ESR(mm) 1 00 1 00 1 00 1 00 
PCV 42.10 2.4 43.14 2.10 42.18 2.12 42.24 2.00 
Values are mean  S.E.M. (Dunnet t' test). *P<0.05; Vs Control N=6. 
 
Table 6. Effect of treatment with Gandhaga Mathirai biochemical parameters. 
Dose (mg/kg) Control 25mg/kg 50mg/kg 100mg/kg 
Total Bilirubin 
(mg/dL) 
0.20 0.05 0.22 0.03 0.22 0.03 0.31 0.05 
Bilirubin direct 
(mg/dL) 
0.00 0.00 0.02 0.01 0.04 0.00 0.02 0.10 
ALP (U/L) 51.12 4.20 48.12 3.84 51.52 2.18 50.11 4.20 
SGOT (U/L) 128.04 4.72 130.11 4.22 132.40 5.10 145.12 4.72* 
SGPT(U/L) 26.21 1.10 27.21 1.22 28.00 1.18 27.24 2.18 
Total Protein(g/dl) 5.10 0.25 5.15 0.24 5.22 0.27 6.00 0.31 
Albumin(g/dl) 3.52 0.06 3.66 0.05 3.12 0.06** 3.35 0.05 
Globulin(g/dl) 3.49 0.12 4.21 0.14* 4.14 0.12* 4.56 0.24** 
Values are mean of 6 animals  S.E.M. *P<0.05; **P<0.01. Vs Control N=6. 
Table-7 RFT 
Dose (mg/kg) Control 25mg/kg 50mg/kg 100mg/kg 
Urea( g/dL) 34.54 4.08 36.12 4.12 37.11 4.20 35.66 4.10 
Creatinine (mg/dL) 30.15 3.10 31.24 3.2 26.10 2.12 29.12  3.1 
Uric acid (mg/dL) 2.38 0.05 1.94 0.05** 2.12 0.08* 2.16 0.08 
Na m.mol 142.45 0.94 144.05 1.02 146.12 1.14 145.02 1.12 
K m.mol 5.58 0.75 5.77 1.00 5.65 0.08 5.75 0.08 
Cl m.mol 104.05 4.42 102.24 4.04 104.52 4.40 103.12 4.23 
Values are mean  S.E.M. *P<0.05;**P<0.01. Vs Control N=6. 
Table-8. Lipid Profile 
Dose (mg/kg) Control 25mg/kg 50mg/kg 100mg/kg 
Total cholesterol (mg/dL) 54.12 4.86 55.12 5.00 55.10 4.78 53.12 4.00 
HDL(mg/dL) 135.02 0.25 138.1 0.21** 143.12 0.27** 152.20 0.26** 
LDL(mg/dL) 72.10 2.61 42.82 3.25** 45.12 3.22** 41.52 3.00** 
VLDL(mg/dl) 25.30 2.14 26.27 2.21 25.31 2.52 26.20 2.44 
Triglycerides (mg/dl) 26.13 4.8 27.10 4.4 25.88 4.0 25.52 4.3 
Blood glucose(mg/dl) 108 10.00 109 10.21 105 12.12 108 10.22 
Values are mean  S.E.M. **P<0.01. Vs Control N=6. 
 
 
Table-9 Urine Analysis 
Parameters 
Control 25mg/kg 50mg/kg 100mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly 
cloudy 
Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >7.5 >7.5 
Protein Nil 1+ 1+ 2+ 
Glucose Nil Nil Nil Trace 
Bilirubin -ve -ve -ve -ve 
Ketones -ve -ve -ve -ve 
Blood Absent Absent Absent Absent 
Urobilinogen 
Normal Normal Normal Normal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
 
 
 
 
 
 
 
 
Table 10. Effect of Gandhaga Mathirai on organ weight 
Dose (mg/kg) Control 25mg/kg 50mg/kg 100mg/kg 
Liver (g) 6.52 0.40 6.70 0.32 6.41 0.30 6.42 0.28 
Heart (g) 1.28 0.05 1.31 0.05 1.14 0.07 1.12 0.05 
Lung (g) 1.82 0.10 1.74 0.05 1.76 0.04 1.64 0.04 
Spleen (g) 0.78 0.04 0.75 0.03 0.76 0.03 0.78 0.04 
Ovary (g) 0.07 0.02 0.08 0.04 0.09 0.04 0.09 0.03 
Testes (g) 2.10 0.14 2.12 0.18 2.20 0.12 2.11 0.14 
Brain (g) 1.88 0.02 1.79 0.03 1.82 0.03 1.90 0.03 
Kidney (g) 1.16 0.03 1.15 0.03 1.18 0.04 1.15 0.03 
Stomach (g) 1.20 0.15 1.22 0.14 1.24 0.16 1.26 0.17 
Values are mean  S.E.M. (Dunnet t' test). nsP>0.05; Vs Control N=6. 
Table-1: Effect of Gandhaga Mathirai on isolated Guinea pig ileum preparation  
 
Values are expressed in mean  SEM, **p< 0.01 compared with histamine induced contraction (30mm as 100%); n=3 
 
Sr. 
No 
Dose of Histamine 
( g/ml) Percent of maximum response 
Histamine alone 
Histamine+Gandhaga 
Mathirai (1mg/ml) 
1 10 2.0 0.10 0.6 0.2** 
2 20 2.4 0.14 0.9 0.2** 
3 40 3.0 0.11 1.2 0.2** 
  Table-1: 
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Values are expressed in mean  SEM, **p< 0.01 compared with histamine induced contraction (30mm as 100%); n=3 
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ANTIHISTAMINIC ACTIVITY OF GANDHAGA MATHIRAI
Histamine Hist+G M(1mg/ml)
Sr. 
No 
Dose of Histamine 
( g/ml) Percent of maximum response 
Histamine alone 
Histamine+Gandhaga 
Mathirai (1mg/ml) 
1 10 2.0 0.10 0.6 0.2** 
2 20 2.4 0.14 0.9 0.2** 
3 40 3.0 0.11 1.2 0.2** 
  
 
 
 
 
 
 
 
 
 
 
 
 
GENDER DISTRIBUTION: 
KAANAKADI 
S.NO GENDER NO.OF 
PATIENTS 
PERCENTAGE 
1. FEMALE 12 60% 
2. MALE 8 40% 
 
 
 
 
 
  
FEMALE  
 
1 FEMALE  
 
2 MALE 
 
 
60%
40%
1
2
AGE  DISTRIBUTION: 
KAANAKADI 
 
 
 
 
 
 
 
 
1    20-30yrs 
2 -  31-40yrs 
3    41-60yrs 
 
 
 
 
 
  
S.NO. AGE NO.OF PATIENTS 
1. 20-30 2(10%) 
2. 31-40 9 (45%) 
3. 41-60 9(45%) 
10%
45%
45%
1
2
3
IMPROVEMENT  SHOWING SIGNS AND SYMPTOMS BEFORE AND AFTER 
TREATMENT OF KAANAKADI PATIENTS. 
 
 
 
 
 
 
 
 
 
S.N
O 
Symptoms Before Treatment               After Treatment 
 
No 
improvemernt 
Improvement 
1 Itching 20(100%) 3(15%) 17 (85%) 
2 wheals 19 (95%) 4 (21.05%) 15 (78.95%) 
3 Rashes 16(80%) 4(25%) 12(75%) 
4 Scratch marks 15(75%) 4(26.67%) 11 (73.33%) 
5 Erythema 16 (80%) 6 (37.5%) 10(62.5%) 
100
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KAANAKADI(URTICARIA) 
Paired t test for Symptoms before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before 
symptoms 
20 
 
4.35  0.87 
 
12.11 P<0.0001 
After 
symptoms 
20 1.05 0.88 
 
For Symptoms the mean and standard deveation before treatment is 4.35   0.87 
and after treatment is 1.05  0.88 which is statistically significant(p<0.0001). 
 
Paired t test for IgE before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before 
symptoms 
20 
 
758.54 680.79 7.63 P<0.0001 
After 
symptoms 
20 597.5 603.31 
 
For IgE ,the mean and standard deveation  before treatment 758.54 680.79 and after 
treatment is 597.5 603.31 which is statistically significant(p<0.0001). 
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KALLEERAL NOI - SCAN REPORT  BEFORE AND AFTER  TREATMENT 
S/NO OP/IP 
NO 
AGE      
 ABDOMINAL       SCAN  
SEX BT  AT  
1 C83364 41 M FATTY LIVER NORMAL STUDY 
2 C91371 30 M NORMAL STUDY NORMAL STUDY 
3 C099363 41 M NORMAL STUDY NORMAL STUDY 
4 C88708 22 M FATTY LIVER NORMAL STUDY 
5 D003387 28 M NORMAL STUDY NORMAL STUDY 
6 C88416 42 M FATTY LIVER NORMAL STUDY 
7 C92427 38 M FATTY LIVER NORMAL STUDY 
8 5051 52 M FATTY LIVER NORMAL STUDY 
9 5022 37 M FATTY LIVER NORMAL STUDY 
10 C97752 33 M NORMAL STUDY NORMAL STUDY 
11 C87304 48 M FATTY LIVER NORMAL STUDY 
12 C93331 42 M NORMAL STUDY NORMAL STUDY 
13 C86858 36 M FATTY LIVER NORMAL STUDY 
14 C82459 36 M NORMAL STUDY NORMAL STUDY 
15 D006570 36 M FATTY LIVER NORMAL STUDY 
16 C96419 48 M FATTY LIVER NORMAL STUDY 
17 C99726 45 M FATTY LIVER NORMAL STUDY 
18 C85775 48 M NORMAL STUDY NORMAL STUDY 
19 C98666 20 M NORMAL STUDY NORMAL STUDY 
20 C81356 50 M FATTY LIVER NORMAL STUDY 
LAB INVESTGATIONS –BEFORE TREATMENT  KALLEERAL NOI 
S/NO OP/IP 
NO 
AGE  Hb 
gm% 
Tccells/cumm  DC   (cells/cumm) ESR BS(gms%) Urea Creatinine T.choles Urine  
 P     L E RBC 1/2 
hr 
1 
hr 
F R/PP Alb Sug Dep 
SEX pus epi 
1 C83364 41 M 15.2 10,000 48 39 9 4.3 4 8 110 124 18 0.4 190 Nil Nil 1 to 2 2 to 4 
2 C91371 30 M 16.2 9,700 64 46 4 5.4 2 4 76 95 20 0.6 226 Nil Nil 2to3 2to3 
3 C099363 41 M 12.6 14,600 63 46 3 3.5 2 4 88 112 18 0.8 164 Nil Nil 2to4 2 to 4 
4 C88708 22 M 17.8 6,300 52 49 2 4.3 2 4 106 110 16 0.5 189 Nil Nil 1to2 2 to 4 
5 D003387 28 M 13.6 7,000 52 26 6 5.6 6 12 90 112 25 0.8 195 Nil Nil 1to2 2to4 
6 C88416 42 M 15 7,200 56 38 5 4.7 4 6 102 122 23 0.5 235 Nil Nil 2 to 4 2 to 4 
7 C92427 38 M 13.7 8,900 48 45 2 4.9 4 8 89 114 22 0.8 225 Nil Nil 2to4 1 to 2 
8 5051 52 M 15.4 9,800 46 38 7 4.8 2 6 95 115 18 0.5 228 Nil Nil 2to3 2to4 
9 5022 37 M 11.6 10,300 79 17 3 4.5 6 12 100 112 17 0.8 150 Nil Nil 1 to 2 2to4 
10 C97752 33 M 16.8 7,900 56 44 3 5.6 2 4 96 110 19 0.8 205 Nil Nil 1to4 1 to 2 
11 C87304 48 M 10.6 7,200 60 38 4 4.3 4 8 98 130 25 0.8 165 Nil Nil 2to3 1to2 
12 C93331 42 M 10.4 8,400 55 35 4 4.9 8 16 96 120 20 0.7 175 Nil Nil 1 to 2 1 to 2 
13 C86858 36 M 16.2 7,100 58 49 2 5.1 6 12 99 126 24 0.8 199 Nil Nil 2to3 2 to 4 
14 C82459 36 M 14.2 6,700 56 36 4 5 2 6 98 115 22 0.8 230 Nil Nil 2to4 1 to 2 
15 D006570 36 M 12.9 8,900 56 36 6 5.2 4 8 86 142 20 0.6 196 Nil Nil 2to3 1to2 
16 C96419 48 M 10.4 6,700 58 38 4 3.7 4 6 80 106 24 0.8 226 Nil Nil 2to4 1 to2 
17 C99726 45 M 10.6 6,900 65 39 3 4.6 6 12 86 116 24 0.8 225 Nil Nil 2to4 2 to 4 
18 C85775 48 M 14.6 7,600 47 39 4 4.7 4 8 110 132 20 0.6 170 Nil Nil 2 to 4 2 to 4 
19 C98666 20 M 14.1 6,300 49 50 2 5.6 4 8 100 126 17 0.6 165 Nil Nil 2to4 2to4 
20 C81356 50 M 14.6 8,600 56 39 4 4.9 2 4 96 1132 22 0.7 185 Nil Nil 2 to 4 2to3 
ACKNOWLEDGEMENT 
 
 I feel immense awe and colossal gratitude in my heart of hearts to God Almighty for 
making this dissertation have its present form. 
 I express my sincere thanks to the Vice-Chancellor, The Tamilnadu Dr.MGR medical 
university Chennai-32. 
 I express my sincere thanks to Prof. Dr.K.Manickavasakam M.D.(S), Director i/c, 
National Institute of Siddha, Tambaram sanatorium,Chennai-47. 
 Its with great pleasure that I express my heartful gratitude to  Dr.M.Rajasekaran 
M.D.(S)., Associate Prof., Head of the Department of Gunapadam i/c, National Institute of 
Siddha,Tambaram sanatorium,Chennai-47, for his encouragement, suggestions and valuable 
guidance in this dissertation work. 
I express my sincere thanks to Dr. Muthuvel, Assistant Professor, Biochemistry 
Dept.,NIS,Chennai-47. 
I express my sincere thanks to Dr.Suba M.Pharm, P.hD., Assistant Professor in 
Pharmacology, NIS, Chennai-47. 
 I express my sincere thanks to Dr.D.Aravind M.D.(S) M.Sc., Assistant Professor, 
Medicinal Botany,NIS,Chennai-47. 
 I express my sincere thanks to Dr.A.Rajendra kumar M.D.(S)., Associate professor, 
Gunapadam department, NIS,Chennai-47, for his suggestions. 
I express my sincere thanks to Dr.S.Visweswaran M.D.(S)., Lecturer, Gunapadam 
department, NIS,Chennai-47, for his suggestions. 
 I express my sincere thanks to Dr.S.Sivakumar M.D.(S)., Lecturer, Gunapadam 
department, NIS,Chennai-47, for his suggestions. 
 I express my sincere thanks to Dr.A.Mariappan M.D.(S)., Lecturer, Gunapadam 
department, NIS,Chennai-47, for his suggestions. 
 I express my grateful  thanks to Dr.Saravana babu, M.Pharm.,Ph.D., SRMC, Porur, 
Chennai. 
 I express my grateful  thanks to Dr.J.Anbu Ph.D., Vels college of pharmacy, 
Pallavaram, Chennai. 
 I express my sincere thanks to Mr.M.Subramanian MSc,SRO, NIS,Chennai-47, for 
his guidance in statistical analysis. 
  
 
LAB INVESTIGATIONS – AFTER TREATMENT KALLEERAL NOI 
S/NO OP/IP 
NO 
AGE  Hb 
gm% 
Tccells/cumm  DC   
(cells/cumm) 
ESR BS(gms%) Urea Creatinine T.choles Urine  
 P     L E RBC 1/2 
hr 
1 
hr 
F R/PP Alb Sug Dep 
SEX pus epi 
1 C83364 41 M 16.4 10,100 48 42 9 4.6 4 8 117 125 14 0.4 156 Nil Nil 1 to 2 2 to 4 
2 C91371 30 M 16.8 9,600 65 46 5 5.6 2 4 75 90 18 0.6 202 Nil Nil 2to3 2to3 
3 C099363 41 M 12.1 14,700 65 40 3 3.5 2 4 86 106 14 0.6 112 Nil Nil 1to2 2 to 4 
4 C88708 22 M 17.7 6,200 50 48 2 4.8 2 4 99 106 16 0.5 161 Nil Nil 1to2 2 to 4 
5 D003387 28 M 13.6 6,900 55 23 6 5.5 4 8 88 106 23 0.6 182 Nil Nil 1to2 1 to 2 
6 C88416 42 M 15.2 7,300 55 39 4 4.6 4 6 96 109 23 0.5 213 Nil Nil 2 to 4 2 to 4 
7 C92427 38 M 13.6 7,400 46 48 2 4.8 4 18 82 105 18 0.4 198 Nil Nil 1 to 2 1 to 2 
8 5051 52 M 15.1 9,800 40 36 6 4.7 2 6 92 110 16 0.5 201 Nil Nil 1to2 2to4 
9 5022 37 M 12 10,500 81 16 3 3.9 4 8 98 105 16 0.5 114 Nil Nil 1 to 2 1 to 2 
10 C97752 33 M 16.6 7,500 55 45 3 5.6 2 4 95 108 17 0.6 195 Nil Nil 0 to 2 1 to 2 
11 C87304 48 M 10.5 7,300 59 33 4 4.2 4 8 95 135 24 0.7 135 Nil Nil 2to3 2 to 4 
12 C93331 42 M 10.6 8,300 58 36 4 4.9 8 16 85 119 18 0.5 135 Nil Nil 1 to 2 1 to 2 
13 C86858 36 M 16.2 7,200 62 48 2 5.2 5 10 95 125 25 0.6 196 Nil Nil  1 to 3 2 to 4 
14 C82459 36 M 14.6 6800 56 37 4 5.2 2 6 90 110 20 0.5 213 Nil Nil 2to3 1 to 2 
15 D006570 36 M 13 8,800 52 34 6 4.9 4 8 80 140 18 0.6 187 Nil Nil 2to3 2to4 
16 C96419 48 M 10.9 5,700 58 36 4 3.7 4 6 75 105 19 0.6 206 Nil Nil 2to4 1 to2 
17 C99726 45 M 10.5 6,800 62 35 3 4.5 4 8 82 112 25 0.5 196 Nil Nil 1 to 2 2 to 4 
18 C85775 48 M 14.5 7,500 46 42 2 4.6 4 8 112 135 20 0.6 160 Nil Nil 2 to 4 2 to 4 
19 C98666 20 M 14.1 6,200 47 49 2 5.5 4 8 98 125 17 0.6 135 Nil Nil 1 to 2 2to4 
20 C81356 50 M 14.7 8,500 52 36 4 4.6 2 4 99 135 21 0.7 170 Nil Nil 2 to 4 2to3 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
  
 
 
 
  
 
 
 
KALLEERAL NOI- SYMPTOMS  BEFORE AND AFTER  TREATMENT 
S NO OP/IPNO AGE SEX ANOREXIA MALAISE NAUSEA VOMITING UPPER AB PAIN JAUNDICE 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 C93331 42 M  +  _  +  _  +  _  _  _  +  _  +  _ 
2 C83364 41 M  +  _  +  _  +  _  +  _  +  _  +  + 
3 C86858 36 M  +  _  +  +  +  _  _  _  _  _  +  _ 
4 C91371 30 M  +  _  _  _   +  +  +  +  +  +  _ _ 
5 C87304 48 M  +  _  +  _  _  _  _  _  +  _  _  _ 
6 C88708 22 M  +  _  +  _  +  _  +  _  +  _  _  _ 
7 C92427 38 M  +  +  +  _  +  _  +  _  +  _  _  _ 
8 5022 37 M  +  +  +  _  +  _  +  +  +  _  +  + 
9 5051 52 M  +  _  _  _  _  _  +  _  _  +  _  _ 
10 C97752 33 M  +  _  +  +  +  +  _  _  +  _  _  _ 
11 C88416 42 M  +  _  +  +  _  _  +  +  +  _  +  _ 
12 D006570 36 M  +  _  +  _  +  +  +  _  +  _  _  _ 
13 C82459 36 M  +  _  +  _  +  +  _  _  _  _  +  + 
14 D003387 28 M  +  _  +  _  _  _  +  _  +  +  _  _ 
15 C96419 48 M  +  _  +  _  +  _  +  _  +  _  _   _ 
16 C099726 45 M  +  _  +  _  +  _  +  _  +  +  _  _ 
17 C099363 56 M  +  _  _  _  +  _  +  _  _  _  +  _ 
18 C85775 48 M  +  +  +  _  +  _  +  _  +  _  _  _ 
19 C98666 20 M  +  _  +  _  +  +  +  _  +  _  _  _ 
20 C81356 50 M  +  _  +  +  +  _  +  _  +  _   _  _ 
                
  
  
 
  
 
 
LAB  INVESTIGATIONS- BEFORE  TREATMENT  KAANAKADI 
S/NO OP/IP 
NO 
Age/sex Hb 
gm% 
Tccells/cumm  DC   
(cells/cumm) 
ESR BS(gms%) Urea Creatinine T.choles Urine  Motion 
P     L E M 1/2 
hr 
1 
hr 
F  PP Alb Sug Dep Ova Cyst Occ.bld 
pus epi    
1 c82635 35/F 10.2 6,300 65 26 2 0 2 4 85 110 12 0.6 164 Nil Nil 4to5 2 to 4 Nil Nil Nil 
2 C83086 32/F 12.6 9,200 56 40 3 0 2 4 76 98 15 0.6 160 Nil Nil 2 to 4 2 to 4 Nil Nil Nil 
3 C83330 39/M 16.8 8,200 61 36 2 0 2 4 85 114 16 0.6 190 Nil Nil 2 to 4 2 to 4 Nil Nil Nil 
4 C84936 37/M 15.2 9,200 54 42 2 0 6 12 83 95 18 0.6 140 Nil Nil 2 to 4 1to3 Nil Nil Nil 
5 C82457 43/F 13.4 6,900 50 46 4 0 6 12 91 115 27 0.7 151 Nil Nil 2 to 4 2to3 Nil Nil Nil 
6 C85487 40/F 12.6 6,400 43 45 3 0 2 6 70 102 20 0.6 176 Nil Nil 2 to 4 2 to 4 Nil Nil Nil 
7 4059 32/F 13.4 8,000 68 30 2 0 6 12 75 110 14 0.4 177 Nil Nil 3to5 1 to 2 Nil Nil Nil 
8 C87414 40/M 15.4 6,300 52 43 4 0 2 8 82 105 18 0.6 155 Nil Nil 2 to 4 1 to 3 Nil Nil Nil 
9 C57248 40/F 13.7 8,200 50 42 2 0 2 6 92 116 14 0.7 145 Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
10 C89054 46/F 10.2 6,200 42 45 2 0 2 6 83 104 14 0.6 140 Nil Nil 1to2 1 to 2 Nil Nil Nil 
11 c90719  46/M 15.2 6,300 55 47 2 0 4 6 103 118 15 0.4 210 Nil Nil 2 to 4 2 to 4 Nil Nil Nil 
12 c92812 42/M 13.6 6,800 50 46 2 0 4 8 72 106 22 0.4 126 Nil Nil 1 to 2 2to4 Nil Nil Nil 
13 C96020 38/M 15.2 6,700 65 22 2 0 2 4 75 98 16 0.6 109 Nil Nil 1to2 2 to 4 Nil Nil Nil 
14 D002764 30/F 13.5 6,700 56 36 4 0 6 12 104 117 16 0.4 130 Nil Nil 2to4 2to4 Nil Nil Nil 
15 C90718 38/F 13.3 8,100 52 42 2 0 4 8 102 118 14 0.6 180 Nil Nil 2to4 2to3 Nil Nil Nil 
16 C89976 45/F 11.6 7,200 58 42 4 0 4 8 98 105 16 0.5 168 Nil Nil 2to4 1 to2 Nil Nil Nil 
17 C94238 42/M 16.3 5,200 60 32 4 0 2 4 96 106 15 0.6 115 Nil Nil 1 to 2 2 to 4 Nil Nil Nil 
18 C82530 36/F 15.2 8,100 65 35 2 0 2 4 84 136 16 0.5 182 Nil Nil 2 to 4 2 to 4 Nil Nil Nil 
19 C90562 29/M 16.2 7,700 66 26 3 0 2 4 102 125 22 0.5 225 Nil Nil 2to4 2to4 Nil Nil Nil 
20 C89780 34/F 12.9 6,600 59 38 4 0 4 8 75 99 16 0.5 202 Nil Nil 1to2 2 to 4 Nil Nil Nil 
LAB  IVESTIGATIONS – AFTER TREATMENT  KAANAKADI 
S/NO OP/IP 
NO 
Age/sex Hb 
gm% 
Tccells/cumm  DC   (cells/cumm) ESR BS(gms%) Urea Creatinine T.choles Urine  Motion 
P     L E M 1/2 hr 1 
hr 
F  PP Alb Sug Dep Ova Cyst Occ.bld 
pus epi    
1 c82635 35/F 10.6 6,200 65 26 2 0 2 4 76 111 14 0.4 164 Nil Nil 3to5 2 to 4 Nil Nil Nil 
2 C83086 32/F 12.1 9,100 53 45 4 0 4 8 86 105 17 0.6 170 Nil Nil 2 to 4 2to3 Nil Nil Nil 
3 C83330 39/M 16.2 8,200 64 38 3 0 2 4 90 102 18 0.4 195 Nil Nil 2to3 2 to 4 Nil Nil Nil 
4 C84936 37/M 15.2 8,900 55 45 2 0 8 14 86 99 20 0.8 150 Nil Nil 2to3 1to3 Nil Nil Nil 
5 C82457 43/F 12.2 7,000 55 43 6 0 6 12 102 116 26 0.8 180 Nil Nil 2 to 4 2to3 Nil Nil Nil 
6 C85487 40/F 12.6 6,500 45 40 6 0 2 6 75 105 22 0.6 193 Nil Nil 2to3 2 to 4 Nil Nil Nil 
7 4059 32/F 10.6 7,800 64 30 4 0 8 16 80 115 18 0.4 189 Nil Nil 3to5 1 to 2 Nil Nil Nil 
8 C87414 40/M 15.4 6,200 50 46 5 0 2 8 76 110 22 0.8 175 Nil Nil 1to2 1 to 3 Nil Nil Nil 
9 C57248 40/F 13.6 8,400 55 46 4 0 4 8 95 118 18 0.8 176 Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
10 C89054 46/F 10 6,100 44 39 4 0 2 6 86 116 22 0.6 465 Nil Nil 1to2 1 to 2 Nil Nil Nil 
11 c90719  46/M 14.8 6,800 55 48 2 0 4 6 106 120 19 0.4 220 Nil Nil 1to2 2 to 4 Nil Nil Nil 
12 c92812 42/M 13.2 6,900 52 48 2 0 4 8 74 109 24 0.4 136 Nil Nil 2to4 2to4 Nil Nil Nil 
13 C96020 38/M 15.6 6,700 64 36 2 0 2 4 86 106 18 0.8 145 Nil Nil 1to2 2 to 4 Nil Nil Nil 
14 D002764 30/F 12.6 6,800 58 54 5 0 6 12 105 119 22 0.6 150 Nil Nil 2to3 2to4 Nil Nil Nil 
15 C90718 38/F 13.6 8,000 55 46 2 0 6 8 99 120 18 0.6 195 Nil Nil 1to2 2to3 Nil Nil Nil 
16 C89976 45/F 13.6 7,100 60 44 4 0 4 8 95 106 22 0.8 189 Nil Nil 1to2 2to3 Nil Nil Nil 
17 C94238 42/M 16.4 5,000 64 45 4 0 2 4 98 117 22 0.8 158 Nil Nil 1 to 2 2 to 4 Nil Nil Nil 
18 C82530 36/F 15.6 8,300 66 45 2 0 2 4 90 135 18 0.6 195 Nil Nil 2 to 4 1to2 Nil Nil Nil 
19 C90562 29/M 15.4 7,600 55 34 3 0 2 4 105 130 22 0.5 230 Nil Nil 2to4 2to4 Nil Nil Nil 
20 C89780 34/F 13 6,700 60 40 4 0 4 8 76 101 18 0.6 209 Nil Nil 1to2 2 to 4 Nil Nil Nil 
  
 
ABDOMEN & KUB SCAN REPORT 
Liver  : Liver shows normal. No abscess or mass lesion seen. Liver measured –  
15.6cms 
Gall bladder : Gall Bladder appeared normal. No calculus seen in gall bladder. CBD  
Appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen  : Spleen appeared normal. Spleen measured 10.5 cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
 
KUB 
RK  : Right Kidney measured 10.1 cms. Cortex and collecting system of right 
kidney  
Appeared normal. No calculi seen.   
LK  : Left Kidney measured 9.8 cms. Cortex and collecting system of left kidney  
Appeared normal. No calculi seen.   
BLADDER : Bladder appeared normal. 
PROSTATE : Prostrate appeared normal. Measured in 3.2 X 2.8 X 2.2 cms (Weight = 15.1  
GMS).No intra vesicle enlargement of prostate gland seen. 
 
IMPRESSION 
Fatty liver  .No other abnormalities seen 
 
 
 
 
 
Patient Name: Mr. KALIDOSS Age/Sex: 41/M 
Patient ID: 9/07/2012_ Visit No: 1 
Referred by: DR.V.JOAN OF ARC Visit Date: 9/07/2012 
  
 
 
ABDOMEN & KUB SCAN REPORT 
Liver  : Liver shows normal. No abscess or mass lesion seen. Liver  
Measured – 12.9cms 
Gall Bladder : Gall Bladder appeared normal. No calculus seen in Gall  
Bladder. CBD appeared normal. No calculus seen in CBD. 
Pancreas : Pancreas appeared normal. 
Spleen : Spleen appeared normal. Spleen measured 9.8cms 
Aorta  : Aorta appeared normal. No Para aortic nodes seen. 
Peritoneal cavity: Peritoneal cavity appeared normal. 
Adrenals : Adrenals appeared normal. 
 
KUB 
RK  : Right Kidney measured 9.5 X 3.9 cms. Cortex and collecting  
System of right kidney appeared normal. No calculi seen. 
LK  : Left Kidney measured 9.7 X 4.1 cms. Cortex and collecting  
System of left kidney appeared normal. No calculi seen.  
BLADDER : Bladder appeared normal. 
PROSTATE : Prostrate appeared normal. Measured in 2.8 X 2.5 X 1.9 cms  
(Weight = 14.4 gms). No intra vesicle enlargement of prostate 
gland seen. 
 
IMPRESSION 
Normal study.  
 
 
Patient Name: Mr. DHARMAMITHRAN Age/Sex: 30/M 
Patient ID: 22/09/2012 Visit No: 1 
Referred by: Dr.V.joan of arc Visit Date: 22/09/2012 
KAANAKADI  SYMPTOMS-BEFORE AND AFTER TREATMENT 
    ITCHING WHEALS RASHES SCRATCH 
MARKS 
ERYTHEMA 
S.NO OP/IP NO AGE SEXX BT AT BT  AT  BT  AT  BT AT  BT  AT  
1 C82635 35 F  + _  +  _  +  _  +  _  +  _ 
2 C83086 32 F  +  _  +  _  +  _  +  _  +  _ 
3 C83330 39 M  +  +  +  +  +  _-  +  _  +  + 
4 C84936 37 M  +  _  +  _  +  +  +  _  _  _ 
5 C82457 43 F  +  _  +  _  +  _  _  _  +  + 
6 C85457 43 F  +  _  +  +  _  _  +  +  _  _ 
7 4059 32 F  +  _  +  _  +  _  +  _  +  _ 
8 C87414 40 M  +  +  +  _  +  _  _  _  +  _ 
9 C57248 40 F  +  _  +  _  _  _  +  _  +  _ 
10 C89054 46 F  +  +  +  _  +  _  +  _  +  _ 
11 C90719 56 M  +  _  +  +  +  _  +  +  _  _ 
12 C92812 42 M  +  _  +  _  _  _  _  _  +  + 
13 C96020 38 M  +  _  +  _  +  _  +  _  +  + 
14 D002764    30 F  +  _  +  _  +  _  +  _  +   + 
15 C90718 38 F  +  _  +  _  +  +  _  _  _  _ 
16 C89976 45 F  +  _  +  +  _  _  +  +  +  + 
17 C94238 42 M  +  _  +  _  +  +   +  +  +  _ 
18 C82530 36 F  +  _  +  _  +  +  _  _  +  _ 
19 C90652 29 M  +  _  _  _  +  _  +  _  +  _ 
20 C89780 34 F  +  _  +  _  +  _  +  _  +  _ 
IgE LEVEL OF KANAKADI PATIENTS BEFORE AND AFTER TREATMENT 
 
   
S NO OP/IPNO AGE SEX  IgE 
IU/ML 
IgE 
IU/ML 
    BT AT 
1 C82635 35 F 396.8 280 
2 C83086 32 F 154.4 98.2 
3 C83330 39 M 231.6 180 
4 C84936 37 M 672.4 522 
5 C82457 43 F 186 123 
6 C85487 40 F 238.6 160.4 
7 4059 32 F 1448 1118 
8 C87414 40 M 248 152 
9 C57248 40 F 1462.7 1272 
10 C89054 46 F 2500 2240 
11 C90719 46 M 1204 999.6 
12 C92812 42 M 583.8 398 
13 C96020 38 M 855 590 
14 D002764 30 F 747.9 502 
15 C90718 38 F 988 763.7 
16 C89976 45 F 413.6 308 
17 C94238 42 M 356.1 236 
18 C82530 36 F 228 158.2 
19 C90562 29 M 2137 1787 
20 C89790 34 F 119 62 
KALLEERAL NOI-  LIVER  FUNCTION  TEST    - BEFORE AND AFTER TREATMENT 
S NO OP/IP 
NO 
AGE SEX BTTB ATTB BTDB ATDB BTIB ATIB BTOT ATOT BTPT ATPT BTALP ATALP BTTP ATTP 
1 C83364 41 M 0.9 0.6 0.3 0.2 0.6 0.4 55 28 46 30 182 172 7.2 7.2 
2 C91371 30 M 0.8 0.4 0.3 0.2 0.5 0.2 46 33 59 24 257 237 7.5 7.4 
3 C099363 56 M 1.3 1.3 0.6 0.5 0.7 0.8 157 90 64 33 202 186 6.9 5.3 
4 C88708 22 M 0.8 0.7 0.3 0.2 0.5 0.4 50 24 48 26 181 195 6.8 6.8 
5 D003387 28 M 1.5 0.5 0.5 0.4 0.3 0.2 55 35 46 36 290 245 6.7 6.3 
6 C88416 42 M 0.4 0.3 0.2 0.2 0.4 0.3 160 75 100 65 153 130 6.9 6.3 
7 C92427 38 M 0.4 0.4 0.3 0.2 0.2 0.2 102 35 94 24 228 205 6.5 6.2 
8 5051 52 M 1.4 1.3 0.6 0.7 0.8 0.5 58 36 40 14 220 216 7 7.2 
9 5022 37 M 0.5 0.3 0.2 0.2 0.3 0.2 78 50 59 45 341 269 6.8 6.5 
10 C97752 33 M 0.9 0.9 0.3 0.3 0.6 0.5 51 24 56 18 216 190 7.4 7.3 
11 C87304 48 M 0.5 0.3 0.2 0.2 0.3 0.2 52 26 46 19 166 176 7.5 7.3 
12 C93331 42 M 0.4 0.2 0.5 0.4 0.4 0.3 74 34 56 32 246 235 6.8 7.8 
13 C86858 36 M 0.7 0.6 0.3 0.3 0.4 0.2 49 32 45 16 200 176 6.7 6.5 
14 C82459 36 M 1.5 1.3 0.5 0.6 0.7 0.8 58 32 52 28 162 175 7.5 7.6 
15 D006570 36 M 1.2 0.9 0.5 0.4 0.7 0.6 96 58 75 53 293 275 6.5 6.2 
16 C96419 48 M 1.9 0.8 0.8 0.4 1.1 0.9 92 25 65 29 241 196 6.1 5.9 
17 C99726 45 M 1.8 0.9 0.4 0.3 0.6 0.5 54 28 49 25 295 254 6.2 6.1 
18 C85775 48 M 0.7 0.6 0.3 0.2 0.4 0.3 75 34 64 38 216 166 7.2 7.7 
19 C98666 20 M 0.5 0.2 0.3 0.3 0.2 0.3 64 26 49 18 216 154 6.2 6.4 
20 C81356 50 M 1.9 1.2 0.3 0.3 1.3 0.4 74 34 65 25 246 174 6 7.6 







 
